

Department of Health & Human Services
Centers for Medicare & Medicaid Services



Annual Report to Congress
On the
Open Payments Program
For Fiscal Year 2014

The Centers for Medicare & Medicaid Services (CMS) strives to make information available to all. Nevertheless, portions of our files including charts, tables, and graphics may be difficult to read using assistive technology.

Persons with disabilities experiencing problems accessing portions of any file should contact CMS through e-mail at 508_Compliance@cms.hhs.gov.

Executive Summary

Open Payments is a national program that promotes transparency by publishing data on the financial relationships between the health care industry (applicable manufacturers and *group purchasing organizations*, or GPOs) and health care providers (physicians and teaching hospitals). In 2014, CMS published 4.45 million payment records, transfers of value, or instances of ownership/investment interest that occurred over the last five months of 2013. These financial transactions totaled nearly \$3.7 billion.

The Affordable Care Act requires the Secretary of the Department of Health and Human Services (HHS) to collect and display information on payments and other transfers of value and ownership/investment interest annually. CMS published information for the first reporting year on its public website, and will update the website annually with a full year of data. This public website is designed to increase access to, and knowledge about, these relationships and provide the public with information to enable them to make informed decisions. Disclosure of the financial relationships between the industry and health care providers is not intended to signify an inappropriate relationship, and Open Payments does nothing to prohibit such transactions. The public can search, download, and evaluate the reported data. The payments and transfers of value and ownership/investment interest displayed on the Open Payments website are self-reported by applicable manufacturers and GPOs.

Partner engagement and outreach efforts are a priority for CMS. Open Payments stakeholders, including medical college faculty, teaching hospital employees, industry professional groups, physicians, attorneys, and compliance professionals, received Open Payments outreach throughout the past year. CMS hosts monthly discussions to share program updates and obtain feedback directly from stakeholders. CMS continues to improve the usability of the public website.

Beginning in 2015 with the reporting of 2014 calendar year data, all data publications will be performed annually and will include a full calendar year of payment data. CMS will publish 2014 financial data by June 30, 2015, as well as updated 2013 data. In addition, every year, CMS will update the Open Payments data at least once after its initial publication. The refreshed data will include updates to data disputes and other data corrections made since the initial publication of this data that were submitted by applicable manufacturers and GPOs.

**Summary of 2013 Program Year Data
August – December, 2013¹**

	Identified Records³	De-Identified Records⁴	Total Published	Total Not Published Due to Delay in Publication⁵
Number of Records²	2.7 million	1.8 million	4.45 million	190,000
Value of payments	\$1.4 billion	\$2.3 billion	\$3.7 billion	\$551 million

¹ Figures are reflective of the December 19th published data refresh.

² A record is defined as a single row in a dataset that was reported by an applicable manufacturer or GPO.

³ An identified record contains identifying information about the recipient of each payment.

⁴ Some records could not be matched by CMS to a single doctor or teaching hospital due to missing or inconsistent information within the submitted record. In an effort to maximize data transparency, CMS published these records as de-identified, with all identifying information about the physician or teaching hospital recipient masked.

⁵ The Open Payments final rule §403.910 provides applicable manufacturers and GPOs the opportunity to request a delay in publication pursuant to certain research payments or under a product research or development agreement for a period not to exceed four calendar years after the date the payment or other transfer of value was made, or upon the approval, licensure or clearance of the covered drug, device, biological, or medical supply by the FDA.

Table of Contents

1. Program Overview and Implementation.....	6
Highlights From the First Year of Open Payments:	6
Statutory Requirement	7
Overview and Implementation of the Open Payments Program.....	8
Program Participants and Roles	9
Engagement and Outreach Efforts.....	12
Program Timeline	13
2. Data Submission and Data Integrity.....	14
Data Submission	14
Data Integrity	14
Penalties for Noncompliance	17
3. Data Collection and Publication: Open Payments System and Public Website.....	18
2013 Summary Information	18
Open Payments System: Planned Improvements for Program Participants.....	19
Open Payments Website: Today	21
Open Payments Website: Planned Enhancements.....	23
Appendix A. Transparency Reports and Reporting of Physician Ownership or Investment Interests, Sec. 1128G. [42 U.S.C. 1320a-7h].....	24
Appendix B. Aggregate Data by Applicable Manufacturer/Group Purchasing Organization (Identified Data).	32

List of Figures

Figure 1. Overview of the Process for Open Payments	9
Figure 2. Open Payments Mobile Application Screenshots.....	11
Figure 3. Example of Aids and Guides for Use With the Open Payments System	15
Figure 4. Example Company Making Payment Search: Summary Information (Search Tool)	22
Figure 5. Detailed Transaction Information (Search Tool)	22

List of Tables

Table 1. Program Participants and Roles	11
Table 2. First Program Year Timeline	13
Table 3. Open Payments Program Payment Types.....	14
Table 4: Open Payments Summary Information	18
Table 5: Open Payments Data Not Published on 12/19/2014 (due to delay in publication requests)**	19
Table 6: Review and Dispute Summary	19
Table 7. Summary of System Enhancements.....	20

1. Program Overview and Implementation

The Affordable Care Act requires the Secretary of the Department of Health and Human Services (HHS) to collect and display information reported by applicable manufacturers and GPOs about the payments and other transfers of value these entities have made to physicians and teaching hospitals, and the ownership or investment interests physicians and their immediate family members have in these entities. CMS developed and implemented the Open Payments program, including the information system built to collect and publish payment information, to fulfill this requirement.

The Affordable Care Act also requires the Secretary to submit an annual report to Congress summarizing: 1.) Information aggregated by applicable manufacturers and GPOs (collectively referred to as industry or reporting entities), and 2.) Any penalties imposed by HHS related directly to Open Payments. CMS consulted with the Office of the Inspector General (OIG) in the development of this report. In addition to summarizing financial transaction information, this report includes plans for improving the program moving forward.

Highlights From the First Year of Open Payments:

- On September 30, 2014, CMS published data records containing 4.4 million payments valued at nearly \$3.5 billion in payments and transfers of value made to physicians and teaching hospitals in the last five months of Calendar Year 2013. This includes ownership or investment interests in applicable manufacturers and GPOs held by physicians or their immediate members, in addition to payments provided for research activities, gifts, speaking fees, meals, or travel.
- For the September 30, 2014 data publication, CMS displayed 2.7 million records containing identifying information about the recipient of each payment. Some records could not be matched by CMS to a single doctor or teaching hospital due to missing or inconsistent information within the submitted record. In an effort to maximize data transparency, CMS published these records as de-identified, with all identifying information about the physician or teaching hospital recipient masked. CMS published a total of 1.7 million de-identified records.
- Since October 30, 2014, CMS has provided applicable manufacturers and GPOs with a non-public list of physician identifier information for physicians found in the 2013 reported data (the Validated Physician List). This list is provided to assist applicable manufacturers and GPOs in preventing many of the inconsistencies identified in submitted data, which were a result of physician identifiers not exactly matching against CMS or external data sources.
- On December 19, 2014, CMS published a data refresh which included an additional 68,000 data records from the last five months of Calendar Year 2013 related to more than \$200 million in financial transactions.

- In total as of December 19, 2014, CMS published data from 1,303 applicable manufacturers and GPOs relating to 4.45 million payment records, transfers of value, or instances of ownership/investment interest. Included in the data submitted by reporting entities were up to 546,000 physicians and 1,360 teaching hospitals.
- During implementation, CMS worked with multiple stakeholders to test the Open Payments system. CMS has hosted, and will continue to host, monthly discussions to share planning activities and hear directly about concerns and challenges.
- As required, CMS has made the data available to the public on a searchable website. CMS will continue to improve public access to Open Payments information and data by making it easier to search and find relevant information to help inform consumers' decision-making. CMS also provides context about payments or transfers of value on the Open Payments website, and applicable manufacturers and GPOs have the ability to provide more context about additional payments.
- The payments and transfers of value displayed on the Open Payments website are self-reported by applicable manufacturers and GPOs. CMS will launch targeted audits of program compliance, as required by the statute, as the program continues to develop.

Statutory Requirement

Section 6002 of the Affordable Care Act amends the Social Security Act (the Act) to add Section 1128G, which mandates the creation of a transparency program. This program, known as Open Payments, requires applicable manufacturers and GPOs of drugs, devices, biologicals, and medical supplies to report payments and other transfers of value made to physicians and teaching hospitals (collectively referred to as covered recipients) for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program (CHIP). Open Payments also requires applicable manufacturers and GPOs to report ownership or investment interests held by physicians or their immediate family members.

The Act requires applicable manufacturers and GPOs to report the required information annually to CMS in an electronic format. Applicable manufacturers and GPOs are subject to civil monetary penalties (CMPs) for failing to comply with these reporting requirements. CMS is required to publish the reported data on a public website. The data must be downloadable, easily searchable, and aggregatable. In addition, CMS must submit annual reports to Congress and each state summarizing the data reported. Section 1128G of the Act generally preempts state laws that require disclosure of the same type of information by manufacturers.

The Affordable Care Act requires the Secretary of HHS to submit an annual report to Congress summarizing aggregate information by manufacturer and GPO and any

penalties imposed by the Department. This first implementation year report complies with the reporting requirements outlined in the Affordable Care Act. The Affordable Care Act also requires consultation with the Office of Inspector General (OIG). CMS consulted with the OIG in the development of this report. Appendix A contains the statutory language and Appendix B contains payments and transfers of value information aggregated by applicable manufacturer and GPO for all identified data.

Overview and Implementation of the Open Payments Program

Open Payments is a national disclosure program that promotes transparency by publishing data on the financial relationships between the health care industry (applicable manufacturers and GPOs) and health care providers (physicians and teaching hospitals) on a public website. This public website is designed to increase access to, and knowledge about, these relationships and provide the public with information to enable them to make informed decisions. The public can search, download, and evaluate the reported data.

Disclosure of the financial relationships between the industry and health care providers is not intended to signify an inappropriate relationship, and Open Payments does nothing to prohibit such transactions. Collaborations among the medical product industry, physicians, and teaching hospitals can contribute to the design and delivery of life-saving drugs, devices, biologicals, and medical supplies. However, these relationships may also influence research, education, and clinical decision-making in ways that compromise clinical integrity and patient care and may potentially lead to increased health care costs. While disclosure alone is not sufficient to differentiate between beneficial financial relationships and those that may create conflicts of interests, transparency aims to shed light on the nature and extent of the relationships that exist and discourage development of inappropriate relationships.

The Affordable Care Act requires CMS to collect and display information reported by applicable manufacturers and GPOs regarding the payments and other transfers of value these entities have made to physicians and teaching hospitals. Once the data is collected by CMS, physicians and teaching hospitals have the opportunity to register in the Open Payments system, review payments attributed to them, and dispute any information reported about them that may be inaccurate. Applicable manufacturers and GPOs then have the opportunity to review and correct information as necessary. CMS displays the data on the public website (Figure 1).

Figure 1. Overview of the Process for Open Payments



CMS published the Open Payments final rule on February 8, 2013 (78 FR 9458). For the 2013 program year and as required in the final rule, applicable manufacturers and GPOs were required to collect data on any payments or other transfers of value, or ownerships and investment interests, occurring between August 1, 2013 and December 31, 2013. Reporting entities were required to report the data to CMS by March 31, 2014.

On September 30, 2014, CMS published data records containing nearly \$3.5 billion in payments and transfers of value to physicians and teaching hospitals made in the last five months of Calendar Year 2013. As required by the final rule, CMS updated the Open Payments data on December 19, 2014, and added new data from the last five months of Calendar Year 2013 so that the dataset totals \$3.7 billion in payments and transfers of value to up to 546,000 individual physicians and 1,303 teaching hospitals. Close to 190,000 records totaling \$551 million in value were not published because the applicable manufacturer requested a delay in publication.

Beginning in 2015 with the reporting of 2014 calendar year data, all future data publications will be performed annually and will include a full 12 months of payment data. CMS will publish the full calendar year of 2014 financial data by June 30, 2015. In addition, every year, CMS will update the Open Payments data at least once after its initial publication. The refreshed data will include updates to data disputes and other data corrections made since the initial publication of this data that were submitted by applicable manufacturers and GPOs.

Program Participants and Roles

As defined in the Act, the term applicable manufacturer means a manufacturer of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States (Section 1128G(e)(2)). Further, the definition of a manufacturer of a covered drug, device, biological, or medical supply means any entity which is engaged in the production, preparation, propagation, compounding, or conversion of a covered drug, device, biological, or medical supply (or any entity under common ownership with such entity which provides assistance or support to such entity with respect to the production,

preparation, propagation, compounding, conversion, marketing, promotion, sale, or distribution of a covered drug, device, biological, or medical supply) (Section 1128G(e)(9)).

As defined in the Act, the term applicable group purchasing organization means a group purchasing organization (as defined by the Secretary) that purchases, arranges for, or negotiates the purchase of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States (Section 1128G(e)(1)).

The Act requires applicable manufacturers and GPOs to annually report to CMS:

- Payments or other transfers of value made to physicians and teaching hospitals.
- Certain ownership or investment interests held by physician owners or investors and their immediate family members.


As defined in the Act, the term covered recipient refers to a physician or a teaching hospital (Section 1128G(e)(6)). Covered recipients include any teaching hospital, defined as an institution that received payment under 1886(d)(5)(B), 1886(h), or 1886(s) of the Act, during the last calendar year for which such information is available.

As further defined in the Open Payments final rule, the term covered recipients includes any physician with an active medical license, except for a physician who is a bona fide employee of an applicable manufacturer or GPO that is reporting the payment (42 C.F.R. §403.902). The term does not, however, cover medical residents.

In accordance with Section 1128G(c)(1)(C)(ix) of the Act, physicians and teaching hospitals can register in the Open Payments system to review data submitted by applicable manufacturers and GPOs prior to public posting, and dispute any information that may be inaccurate.

While not required to participate in Open Payments, CMS encourages physicians and teaching hospitals to participate in the program. In an effort to facilitate participation, CMS released two mobile applications (mobile apps) that serve as interactive tools to be used by physicians and industry. One app is targeted specifically to physicians (Open Payments Mobile for Physicians) and the other is for industry, including applicable manufacturers and GPOs (Open Payments Mobile for Industry). Figure 2 shows screenshots of each of the apps. Access the mobile apps through the Open Payments website at <http://www.cms.gov/OpenPayments/About/Mobile-Apps.html>.

Figure 2. Open Payments Mobile Application Screenshots



Registration in the Open Payments system is voluntary for physicians and teaching hospitals, but if a physician or teaching hospital wants the opportunity to review and dispute data attributed to them for the reporting period, they must register in the Open Payments system.

CMS’s role in the Open Payments program is to collect and publish information from applicable manufacturers and GPOs regarding payments and transfers of value to physicians and teaching hospitals, as well as ownership and investment interests (Table 1). CMS also provides extensive outreach and education to the health care industry, physicians, teaching hospitals, and the general public to inform them about this new program. CMS has provided and will continue to provide technical assistance, guidance, and resources to all Open Payments stakeholders.

Table 1. Program Participants and Roles

Program Participants	Roles				
	Register in the Open Payments System	Submit Data	Review & Dispute Data	Address Disputes	Publish Data
CMS					✓
Manufacturers & GPOs (Required)	✓	✓		✓	
Physicians & Teaching Hospitals (Voluntary)	✓		✓		

Engagement and Outreach Efforts

In accordance with Section 1128G(c)(1)(C) of the Act, CMS solicited stakeholder assistance in the development of our public website. CMS met with multiple stakeholders and received feedback about context for the published information that would be useful to consumers. With the assistance of this feedback, CMS produced and published specific language for consumers to help them understand the various natures of payments and provided examples of such payments. A number of applicable manufacturers participated in user acceptance testing of the system itself, testing the system by performing tasks such as registering, viewing records, and uploading data. Those involved in system testing provided valuable feedback that contributed to system improvements and better instructional documents for all system users.

Partner engagement and outreach efforts are a priority for CMS. Open Payments stakeholders, consisting of but not limited to, medical college faculty, teaching hospital employees, physicians, attorneys, and compliance professionals received regular Open Payments outreach throughout the past year.

CMS undertook a robust outreach and education campaign to support this first program year, using tools such as electronic listserv messaging, social media, webinars, stakeholder meetings and conference calls, blogs, CMS Regional Office engagements, and electronic news disseminations. CMS distributed 13 Medicare Learning Network (MLN) Connects messages on various Open Payments updates, including key deadlines and background information. MLN Connects reached 134 provider partners representing more than 3.2 million members. More than 35,000 physicians and teaching hospitals signed up to receive listserv messages from Open Payments, and CMS reached an additional 175,000 physicians using other CMS listservs. CMS Regional Offices published articles on their websites and in e-newsletters, which reached more than 14,000 provider partners and approximately 750,000 providers. Through the official CMS Twitter account, tweets regarding Open Payments developments were shared throughout the campaign and had an approximate exposure of 58,000 followers per tweet. And finally, more than 14 million impressions (i.e., the number of times a digital ad was displayed on a web page) were tabulated through digital advertising avenues.

CMS conducted a number of focus groups with different stakeholders including physicians and the general public, to get their impressions of the program as well as collect critical feedback that was used to optimize CMS's messaging and outreach efforts, including the development of content for the Open Payments website.

CMS has also been committed to working with states. In accordance with Section 1128G(d)(2) of the Act, CMS provided formal notification to states on September 30, 2014 that state-specific information was available through the public website. The website allows states to aggregate and filter their data, as well as create state-specific visualizations.

Program Timeline

Applicable manufacturers and GPOs began data submissions on February 18, 2014 (Table 2). CMS implemented quality control and review and dispute processes between February and September 30, 2014 when the data was published. CMS published a refresh of the data, including previously unpublished payment records, on December 19, 2014.

Table 2. First Program Year Timeline

Program Activity	Date(s) in 2014
Industry registered and submitted data in Open Payments system <ul style="list-style-type: none"> Phase 1: CMS Enterprise Identity Management (EIDM*) registration, submission of corporate profile information, and aggregate 2013 payment data Phase 2: Open Payments system registration, submission of detailed 2013 payment data, and legal attestation to the accuracy of the data 	Feb. 18 – March 31 June 1 – June 30
Physicians and teaching hospitals registered <ul style="list-style-type: none"> EIDM registration only EIDM and Open Payments registration** 	Started June 1 Started July 14
Industry attested to data accuracy (deadline for completion without being subject to CMS imposing CMPs)	July 7
Physicians and teaching hospitals reviewed and disputed data	July 14 – Sept. 11***
Industry made corrections to data as necessary	Sept. 11 – Sept. 26****
Data published by CMS	Sept. 30
Report to states made available	Sept. 30
Search tool released	Oct. 17
Industry made corrections to data as necessary	Oct. 17 – Oct. 31†
2013 data refresh published by CMS	Dec. 19
* EIDM is the CMS authentication gateway used to allow the public access to a number of CMS systems. EIDM is the first authentication step in a two-step process to access the Open Payments system. ** continuous enrollment made available *** this was not a continuous period of time; review and dispute functionality was open for 45 days **** 9/11/2014 to 9/26/2014 constitutes the correction period that occurred prior to the 9/30/2014 data publication † 10/17/2014 to 10/31/2014 constitutes the correction period that occurred in accordance with the requisite annual data refresh and data publication on 12/19/2014 Note: Some program activities were specific to the first year of implementation and may not be repeated in subsequent reporting years.	

2. Data Submission and Data Integrity

Data Submission

Data submitted by applicable manufacturers and GPOs are categorized across three main payment types: general payments, research payments, and physician ownership information (Table 3).

Table 3. Open Payments Program Payment Types

General Payments	Research Payments	Physician Ownership Information
Payments or other transfers of value not made in connection with a research agreement or research protocol.	Payments or other transfers of value made in connection with a research agreement or research protocol.	Information about physicians or their immediate family members who have an ownership or investment interest in an applicable manufacturer or GPO.

As defined in the Act, payment data also identifies the nature of each payment, such as consulting fees, research grants, travel reimbursements, and other gifts applicable manufacturers or GPOs provide to physicians and teaching hospitals (Section 1128G(a)(1)(A)(vi)). CMS has information and examples on our website to help consumers understand the various natures of payments.

In accordance with the Open Payments final rule, certain research payments or other transfers of value made to a covered recipient by an applicable manufacturer under a product research or development agreement may be delayed from publication on the Open Payments website. Delayed publication of a payment or other transfer of value can be requested by an applicable manufacturer when made in connection with research on or development of (or clinical investigations regarding) a new drug, device, biological, or medical supply, or a new application of an existing drug, device, biological, or medical supply. CMS makes these payments available for physician review, and can delay publication for up to four years. Such optional delays in publication are part of the program, as required by statute, to help balance public interest in transparency with innovation in product design and research.

Data Integrity

CMS provided applicable manufacturers and GPOs with numerous aids and guides to assist with data submission. These support materials included the annually-updated teaching hospital list, submission data mapping documents, sample submission files, the Open Payments System User Guide, step-by-step detailed instructions, and quick reference guides (Figure 3). With the assistance of these materials, applicable manufacturers and GPOs submitted attested data into the Open Payments system, and CMS performed initial matching of data to a physician or teaching hospital. After the data was collected and made available for review within the Open Payments system,

registered physicians and teaching hospitals had the opportunity to review payments attributed to them and dispute information they believed to be inaccurate.

Figure 3. Example of Aids and Guides for Use With the Open Payments System

Open Payments Quick Reference Guide – Physician Registration

Register in EIDM

1. Visit the [CMS Enterprise Portal](#) and select "New user registration."
2. Accept the terms and conditions, being sure to read the "Consent to monitoring" and "Collection of personal identifiable information" sections. Identity verification is required for all users requesting access to any CMS application.
3. Enter your personal information. Completing all fields, including those not required, will speed up the approval process.
4. Select your user ID, password and security questions.
5. Complete registration and wait for confirmation email.

Request Access to Open Payments

1. Log in to the CMS Enterprise Portal.

ID #	Data Element Name	Definition / Description	Data Type	Format	Required?	Field Size	Validation	Publicly Shared?	EID Element Name
1	Applicable Manufacturer or Applicable GPO Name	The user must enter either the following Applicable Manufacturer or Submitting Applicable Group Purchasing Organization (GPO) name: If this file contains a single Applicable Manufacturer/Applicable GPO set of (manufacturer/treatment records, this Applicable Manufacturer/Applicable GPO name will be used for all records in the file. If this file contains a Consolidated Report, this Applicable Manufacturer/Applicable GPO Name will be used in the Consolidated Report and the Applicable Manufacturer/Applicable GPO Name and Clear Payments system ID of the sub-components related to the (manufacturer/treatment will be included with every payment or transfer of value record in the file.	Text	Free text field	Yes	1-100 Char	Match the name on the file for associated Registration ID	Yes	ApplicableManufacturerID/ApplicableGPOName
2	Applicable Manufacturer or Applicable GPO Registration ID	Clear Payments system generated identifier used to identify the Applicable Manufacturer or Applicable GPO (associated only with the CMS provider identifier). If this file contains a single Applicable Manufacturer/Applicable GPO set of (manufacturer/treatment records, this Applicable Manufacturer/Applicable GPO name will be used for all records in the file. If this file contains a Consolidated Report, this Applicable Manufacturer/Applicable GPO Name will be used in the Consolidated Report and the Applicable Manufacturer/Applicable GPO Name and Clear Payments system ID of the sub-components related to the (manufacturer/treatment will be included with every payment or transfer of value record in the file.	Numeric	System generated	Yes	System generated Number 10000	Match the Registration ID on the file	No	ApplicableManufacturerID/ApplicableGPOID
3	Consolidated Report Indicator	Indicator showing if this submission file contains a Consolidated Report.	Boolean	Y = Yes, N = No	Yes	1 Char	Limited to characters Y or N	No	ConsolidatedReportIndicator
4	Manufacturer File Indicator	Indicator showing if this submission file contains information that is associated or transferred to a manufacturer of a submission record.	Boolean	Y = Yes, N = No	Yes	1 Char	Limited to characters Y or N	No	ManufacturerFileIndicator
5	Physician's First Name	The user must enter, as listed in the National Plan & Provider Enumeration System (NPPES) of the physician with the (manufacturer or treatment record being reported).	Text	Free text field	Yes	1-20 Char	Validation by CMS	Yes	PhysicianFirstLastName
6	Physician's Middle Name	The user must enter, as applicable, as listed in the National Plan & Provider Enumeration System (NPPES) of the physician with the (manufacturer or treatment record being reported).	Text	Free text field	No	1-20 Char	Validation by CMS	Yes	PhysicianMiddleName
7	Physician's Last Name	The user must enter, as listed in the National Plan & Provider Enumeration System (NPPES) of the physician with the (manufacturer or treatment record being reported).	Text	Free text field	Yes	1-30 Char	Validation by CMS	Yes	PhysicianLastLastName

More than 26,000 physicians and 400 teaching hospitals registered in the Open Payments system to review payments attributed to them. 12,579 payment records were disputed during the review and dispute period, approximately 9,000 of which remained disputed at the end of the review and dispute period. During this period, CMS identified payment records that had intermingled physician information, such as National Provider Identifier (NPI) for one doctor combined with the state medical license number for another.

CMS took the Open Payments system offline on August 3, 2014, to resolve these data integrity issues and reopened the system on August 14, 2014. During this period, CMS worked to verify that the physician and teaching hospital identifiers reported by applicable manufacturers and GPOs matched data in CMS or external data sources. This matching verified that payment records were attributed to a single, consistent physician or teaching hospital. As a result of this process, some payment records within the system were invalidated and required correction and resubmission by applicable manufacturers and GPOs.

These invalid payment records were removed from the review and dispute process (and later provided in Removed Records Reports for industry review on October 30, 2014). Records submitted in the Open Payments system were considered invalid if:

1. For general or research payment records submitted for physicians who have an NPI, including covered principal investigators,
 - a. the NPI, state license information, and first and last names reported for the physician in the record were not an exact match against CMS or external data sources, or
 - b. the physician in the record had a NPI according to CMS data sources, but the NPI was not reported in the record as required by regulations (42 C.F.R. §403.904(c)(3)(ii)).
2. For general or research payment records submitted for physicians who do not have an NPI, including covered principal investigators—the state license information and first and last names reported in the record were not an exact match against CMS or external data sources which acquire licensure data from state licensure boards.
3. For records submitted by a GPO, a physician in a general or research payment record did not also have an ownership interest record submitted for that same GPO as required by regulations (42 C.F.R. §403.906(b)(6)).
4. For general or research payment records submitted for teaching hospitals, the legal business name and TIN reported in the record were not an exact match against the CMS provided list of approved teaching hospitals.

In cases where CMS was unable to match the physician information or the record was not available for review and dispute, but the company had attested that the payment had been made, any identifying information about the covered recipient was masked in the published data, and the data was published as de-identified.


CMS initially displayed 2.7 million (out of 4.4 million) records that included identified physicians or teaching hospitals. This initial data display also included 1.7 million de-identified records. To maximize transparency and release as much data as possible, records that could not be matched by CMS to a single doctor or teaching hospital due to missing or inconsistent information within the submitted records were published as de-identified. The goal is for this data to be fully identified in 2015 after the reporting entity submits corrected data and physicians and teaching hospitals have a chance to review and dispute. Data that was disputed and not resolved by the end of the September 2014 review period was not published on September 30, 2014, but was published during the data refresh on December 19, 2014.

Beginning on October 30, 2014, applicable manufacturers and GPOs had the opportunity to review and correct 2013 payment records returned from the intermingled data fix that went into effect in August. Within the Open Payments system, applicable manufacturers and GPOs were able to download a Removed Records Report which showed which records across all three payment types were removed (e.g., published in a de-identified manner) from the published identified data and why each individual record was removed. After reviewing this report, applicable manufacturers

and GPOs had the ability to resubmit corrected records. These records will go through the same submission, review and dispute, and public posting process as all identified data goes through.

Also on October 30, 2014, CMS made a non-public, downloadable Validated Physician List available to applicable manufacturers and GPOs in the Open Payments system. This list contains variations of physician identifier information for physicians to whom payments were reported in the Open Payments system in 2013, and is provided to assist with data matching. Many of the inconsistencies identified in the returned records were a result of physician identifiers not matching against CMS or external data sources. CMS has encouraged applicable manufacturers and GPOs to use the provided physician list to avoid further inconsistencies in data reporting. CMS anticipates releasing similar lists for upcoming years for industry use.

Penalties for Noncompliance



The payments and transfers of value displayed on the Open Payments website are self-reported by applicable manufacturers and GPOs. In accordance with Sections 1128G(b)(1) and 1128G(b)(2) of the Act, CMS will launch targeted audits to identify applicable manufacturers and GPOs that should have submitted payment information but did not for 2013.

As of the date of this publication, CMS is engaged in an effort to increase submission compliance of specific entities that did not submit data.

The near-term objectives of the Open Payments compliance strategy are focused on alerting applicable manufacturers and GPOs to their failure to register and submit data in the Open Payments system. Beyond the first program year, applicable manufacturers and GPOs will be notified of their failure to report in a timely, accurate and/or complete manner. To date, CMS has not imposed any CMPs against applicable manufacturers or GPOs.

3. Data Collection and Publication: Open Payments System and Public Website

2013 Summary Information

CMS published data records related to \$3.5 billion in payments and transfers of value, plus ownership and investment interests, on the Open Payments website on September 30, 2014. Subsequently, CMS published a refresh of the data on December 19, 2014, with information on over \$200 million in additional data records (Table 4). Aggregate submission data by manufacturer and GPO, for all identified data, can be found in Appendix B.

Table 4: Open Payments Summary Information

Categories	Total
Open Payments Data Published on 12/19/2014	
Total value	\$3.7 billion*
Total number of records	4.45 million*
Total number of physicians	366,000*+
Total number of teaching hospitals	900*^
Total number of applicable manufacturers and GPOs	1,303
Open Payments Identified Data Published on 12/19/2014⁺⁺	
Value	\$1.4 billion*
Number of records	2.7 million*
Number of physicians	366,000*
Number of teaching hospitals	900*
Number of applicable manufacturers and applicable GPOs	1,219
Open Payments De-Identified Data Published on 12/19/2014	
Value	\$2.3 billion*
Number of records	1.8 million*
Number of covered recipient physicians	Not published on 12/19/2014 ⁺⁺⁺
Number of teaching hospitals	
Number of reporting applicable manufacturers and GPOs in the published data on 12/19/2014	1,186
* rounded	
+ up to 546,000 (rounded) based on possible physician identifier inconsistencies within de-identified data	
^ up to 1,360 (rounded) based on possible teaching hospital identifier inconsistencies within de-identified data	
⁺⁺ 1,379 is the number of applicable manufacturers and GPOs with reported data as of 7/7/2014	
⁺⁺⁺ these data will be published during a future Open Payments program cycle	

Table 5 provides a summary of data that were reported to CMS, but were not published in the December 19, 2014, Open Payments data publication due to delay in publication requests. As summarized in Table 6, over 26,000 physicians registered in the Open Payments system to participate in the review and dispute process. Through the process,

nearly 30 percent of the 12,579 disputed records were resolved prior to the September 30, 2014, publication date.

Table 5: Open Payments Data Not Published on 12/19/2014 (due to delay in publication requests)**

Categories	Total
Value of records	\$551 Million*
Number of records	190,000*
* rounded	
** The Open Payments final rule §403.910 provides applicable manufacturers and GPOs the opportunity to request a delay in publication for a period not to exceed four calendar years after the date the payment or other transfer of value was made, or upon the approval, licensure or clearance of the covered drug, device, biological, or medical supply by the FDA. Publication of research payment records may be delayed by submitter request if the records relate to research or development of a new drug, biological, device, or medical supply; a new application of a drug, biological, device, or medical supply; or clinical investigations regarding a drug, biological, device, or medical supply.	

Table 6: Review and Dispute Summary

Categories	Data Published 9/30/2014
Number of physicians that registered in Open Payments system to review and dispute	26,000*
Number of teaching hospitals that registered Open Payments system to review and dispute	405
Number of records that were disputed	12,579
Number of unresolved disputes at the end of review period	9,000*
Number of records that were affirmed	17,994**
* Rounded	
** "Affirmed" indicator signifies that the covered recipient associated with the reported record has reviewed it and agreed with its accuracy.	

Open Payments System: Planned Improvements for Program Participants

A number of stakeholders are substantively engaged in the Open Payments program. CMS hosts monthly meetings to share program updates and hear directly from stakeholders about their areas of concerns and challenges. CMS worked with multiple system users during the implementation of the Open Payments system as pilot testers. In addition, CMS has hosted discussions and focus groups during the implementation of the program.

CMS is making multiple system enhancements based on stakeholder feedback. In 2015, the following upgrades to the Open Payments system will be applied (Table 7):

- More intuitive and user-friendly system screens, including just-in-time guidance via on-screen messages, which provide guidance directly at the point in the process where users require it.

- Record download capability for applicable manufacturers and GPOs, allowing them to download records already reported into the Open Payments system.
- Improved user identity management approach that ensures fully synchronized user accounts between EIDM and Open Payments.
- Enhancements to enable deactivation of users no longer requiring access to the system.
- Enhancements to the review and dispute functionality for physicians and teaching hospitals, including enabling covered recipient primary investigators to dispute their associations with the research study to which the reported payment was related.
- Enhanced matching logic used to attribute transactions reported by applicable manufacturers and GPOs to correct covered recipients. The upgraded matching logic will minimize the chances of conflicting data being processed by the system and data being attributed improperly.

Table 7 illustrates a summary of system enhancements, broken out by participant group and the system area impacted by each enhancement.

Table 7. Summary of System Enhancements

Participant Group	System Area: Enhancement
Physicians & Teaching Hospitals (Voluntary)	<ul style="list-style-type: none"> • Registration: Physicians cannot edit first name, last name, or NPI after vetting is successful. • Registration: E-mails will now be sent to physicians regarding status of vetting process. • Review and Dispute: Principal investigators will now have the ability to review research records attributed to them and dispute their association with the reported payment. All other details such as payment amount, date, nature of payment, can only be disputed by the covered recipient.
Manufacturers & GPOs (Required)	<ul style="list-style-type: none"> • Data Submission: Validated Physician List now available, along with annually-published Teaching Hospital List. • Data Submission: Deleting records will trigger re-attestation. • Data Submission: “Unmatched” records are treated as validation errors and cannot be overridden. • Data Submission: XML is no longer an accepted bulk data file format.
All program participants (Required and Voluntary)	<ul style="list-style-type: none"> • Registration: Special characters are now allowed in physician and entity names and state license numbers. • Data Submission: Enhanced data matching for submitted records. • Review and Dispute: “Delay in Publication” status is now visible on Review Records page.

CMS continuously analyzes user feedback received by the Open Payments Help Desk and through direct engagements with industry and the medical community. CMS will continue to use that feedback to guide future system enhancements.

Open Payments Website: Today

CMS launched a redesigned Open Payments website on September 30, 2014, to support the release of Open Payments data and to include more contextual information about the program. The site continues to provide the necessary resources for all program participants, applicable manufacturers and GPOs that are required to report financial transactions and physicians and teaching hospitals that choose to register in the Open Payments system. On the website, visitors can find information explaining how the program works, why it was implemented, and how users can explore all the data CMS has published. CMS provided a field in the Open Payments system for applicable manufacturers and GPOs to voluntarily supply contextual information for each individual payment or transfer of value record submitted. This contextual information provided by applicable manufacturers and GPOs is now available to view on the public website. In addition to contextual information and resources for program participants, the site now displays the first reporting year of Open Payments data. CMS developed the Open Payments website using a three-pronged data delivery approach:

1. **Data downloads:** Users can select a dataset and [download the data](#) in comma-separated values (.csv) format, which allows users to open and explore the data using their own software on their own computer. With this option, the user is not reliant upon an internet connection to view the data, but must have software that allows for downloading and viewing data in large datasets.
2. **Data Explorer:** Using the Data Explorer [web-based interface](#), users can select a dataset then customize the view using filters, sorts, and other actions to create their own, targeted views of the data. The Data Explorer interface allows users to create visualizations such as charts and graphs to interact with the data visually.
3. **Search Tool:** Site visitors can get immediate results using this [standard search interface](#) to find information on individual physicians, teaching hospitals, or reporting entities. Site visitors can also view payment totals for an individual or entity, and select single records to see all the details associated with that particular piece of data, including any contextual information associated with that transaction (Figures 4 and 5).

Figure 4. Example Company Making Payment Search: Summary Information (Search Tool)

For Illustrative Purposes Only





Figure 5. Detailed Transaction Information (Search Tool)



For Illustrative Purposes Only

From September 30 – December 31, 2014, nearly 500,000 site visitors used our informational site to learn more about Open Payments or access resources for interacting with the Open Payments system. In that same timeframe, close to 1 million visitors accessed Open Payments data through the search or Data Explorer tool, and Open Payments data has been downloaded over 13,500 times. Major news outlets such as the Wall Street Journal and the New York Times, professional journals including the Journal of the American Medical Association, and special interest groups like Pro Publica have all published articles, blogs, and data visualizations based on the published Open Payments data.

Openpaymentsdata.cms.gov hit an all-time high for pageviews in direct response to an increase in social media attention. During the week of February 8, 2015, to February 14, 2015, the Open Payments search tool and data explorer delivered approximately 2.5 million unique pageviews to site visitors.

Open Payments Website: Planned Enhancements

CMS plans to provide summary information of all Open Payments data in a data dashboard layout. Similar to the data summary fact sheet CMS already provides on the Open Payments [website](#), this dashboard will give visitors an aggregate view of all Open Payments data by providing statistics such as total dollar amount of all payments and transfers of value, total number of entities that made payments, and total number of physicians who received payments.

CMS also continues to solicit stakeholder assistance to make enhancements to the public website. Combining this feedback with 2014 data to be published in June, 2015, CMS will provide more opportunities for all site visitors, from the advanced data user to the general public, to discover meaningful information in the Open Payments data published by CMS.

Appendix A. Transparency Reports and Reporting of Physician Ownership or Investment Interests, Sec. 1128G. [42 U.S.C. 1320a-7h]

SEC. 1128G. [42 U.S.C. 1320a-7h]

(a) TRANSPARENCY REPORTS.—

(1) PAYMENTS OR OTHER TRANSFERS OF VALUE.—

(A) IN GENERAL.—On March 31, 2013, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer that provides a payment or other transfer of value to a covered recipient (or to an entity or individual at the request of or designated on behalf of a covered recipient), shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information with respect to the preceding calendar year:

(i) The name of the covered recipient.

(ii) The business address of the covered recipient and, in the case of a covered recipient who is a physician, the specialty and National Provider Identifier of the covered recipient.

(iii) The amount of the payment or other transfer of value.

(iv) The dates on which the payment or other transfer of value was provided to the covered recipient.

(v) A description of the form of the payment or other transfer of value, indicated (as appropriate for all that apply) as—

(I) cash or a cash equivalent;

(II) in-kind items or services;

(III) stock, a stock option, or any other ownership interest, dividend, profit, or other return on investment; or

(IV) any other form of payment or other transfer of value (as defined by the Secretary).

(vi) A description of the nature of the payment or other transfer of value, indicated (as appropriate for all that apply) as—

(I) consulting fees;

(II) compensation for services other than consulting;

(III) honoraria;

(IV) gift;

(V) entertainment;

(VI) food;

- (VII) travel (including the specified destinations);
- (VIII) education;
- (IX) research;
- (X) charitable contribution;
- (XI) royalty or license;
- (XII) current or prospective ownership or investment interest;
- (XIII) direct compensation for serving as faculty or as a speaker for a medical education program;
- (XIV) grant; or
- (XV) any other nature of the payment or other transfer of value (as defined by the Secretary).

(vii) If the payment or other transfer of value is related to marketing, education, or research specific to a covered drug, device, biological, or medical supply, the name of that covered drug, device, biological, or medical supply.

(viii) Any other categories of information regarding the payment or other transfer of value the Secretary determines appropriate.

(B) SPECIAL RULE FOR CERTAIN PAYMENTS OR OTHER TRANSFERS OF VALUE.—In the case where an applicable manufacturer provides a payment or other transfer of value to an entity or individual at the request of or designated on behalf of a covered recipient, the applicable manufacturer shall disclose that payment or other transfer of value under the name of the covered recipient.

(2) PHYSICIAN OWNERSHIP.—In addition to the requirement under paragraph (1)(A), on March 31, 2013, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information regarding any ownership or investment interest (other than an ownership or investment interest in a publicly traded security and mutual fund, as described in section 1877(c)) held by a physician (or an immediate family member of such physician (as defined for purposes of section 1877(a))) in the applicable manufacturer or applicable group purchasing organization during the preceding year:

(A) The dollar amount invested by each physician holding such an ownership or investment interest.

(B) The value and terms of each such ownership or investment interest.

(C) Any payment or other transfer of value provided to a physician holding such an ownership or investment interest (or to an entity or individual at the request of or designated on behalf of a physician holding such an ownership or investment interest), including the information described in clauses (i) through (viii) of paragraph (1)(A),

except that in applying such clauses, 'physician' shall be substituted for 'covered recipient' each place it appears.

(D) Any other information regarding the ownership or investment interest the Secretary determines appropriate.

(b) PENALTIES FOR NONCOMPLIANCE.—

(1) FAILURE TO REPORT.—

(A) IN GENERAL.—Subject to subparagraph (B) except as provided in paragraph (2), any applicable manufacturer or applicable group purchasing organization that fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than \$1,000, but not more than \$10,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1128A are imposed and collected under that section.

(B) LIMITATION.—The total amount of civil money penalties imposed under subparagraph (A) with respect to each annual submission of information under subsection (a) by an applicable manufacturer or applicable group purchasing organization shall not exceed \$150,000.

(2) KNOWING FAILURE TO REPORT.—

(A) IN GENERAL.—Subject to subparagraph (B), any applicable manufacturer or applicable group purchasing organization that knowingly fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than \$10,000, but not more than \$100,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1128A are imposed and collected under that section.

(B) LIMITATION.—The total amount of civil money penalties imposed under subparagraph (A) with respect to each annual submission of information under subsection (a) by an applicable manufacturer or applicable group purchasing organization shall not exceed \$1,000,000.

(3) USE OF FUNDS.—Funds collected by the Secretary as a result of the imposition of a civil money penalty under this subsection shall be used to carry out this section.

(c) PROCEDURES FOR SUBMISSION OF INFORMATION AND PUBLIC AVAILABILITY.—

(1) IN GENERAL.—

(A) ESTABLISHMENT.—Not later than October 1, 2011, the Secretary shall establish procedures—

(i) for applicable manufacturers and applicable group purchasing organizations to submit information to the Secretary under subsection (a); and

(ii) for the Secretary to make such information submitted available to the public.

(B) DEFINITION OF TERMS.—The procedures established under subparagraph (A) shall provide for the definition of terms (other than those terms defined in subsection (e)), as appropriate, for purposes of this section.

(C) PUBLIC AVAILABILITY.—Except as provided in subparagraph (E), the procedures established under subparagraph (A)(ii) shall ensure that, not later than September 30, 2013, and on June 30 of each calendar year beginning thereafter, the information submitted under subsection (a) with respect to the preceding calendar year is made available through an Internet website that—

(i) is searchable and is in a format that is clear and understandable;

(ii) contains information that is presented by the name of the applicable manufacturer or applicable group purchasing organization, the name of the covered recipient, the business address of the covered recipient, the specialty of the covered recipient, the value of the payment or other transfer of value, the date on which the payment or other transfer of value was provided to the covered recipient, the form of the payment or other transfer of value, indicated (as appropriate) under subsection (a)(1)(A)(v), the nature of the payment or other transfer of value, indicated (as appropriate) under subsection (a)(1)(A)(vi), and the name of the covered drug, device, biological, or medical supply, as applicable;

(iii) contains information that is able to be easily aggregated and downloaded;

(iv) contains a description of any enforcement actions taken to carry out this section, including any penalties imposed under subsection (b), during the preceding year;

(v) contains background information on industry physician relationships;

(vi) in the case of information submitted with respect to a payment or other transfer of value described in subparagraph (E)(i), lists such information separately from the other information submitted under subsection (a) and designates such separately listed information as funding for clinical research;

(vii) contains any other information the Secretary determines would be helpful to the average consumer;

(viii) does not contain the National Provider Identifier of the covered recipient, and

(ix) subject to subparagraph (D), provides the applicable manufacturer, applicable group purchasing organization, or covered recipient an opportunity to review and submit corrections to the information submitted with respect to the applicable manufacturer, applicable group purchasing organization, or covered recipient, respectively, for a period of not less than 45 days prior to such information being made available to the public.

(D) CLARIFICATION OF TIME PERIOD FOR REVIEW AND CORRECTIONS.—In no case may the 45-day period for review and submission of corrections to information under subparagraph (C)(ix) prevent such information from being made available to the public in accordance with the dates described in the matter preceding clause (i) in subparagraph (C).

(E) DELAYED PUBLICATION FOR PAYMENTS MADE PURSUANT TO PRODUCT RESEARCH OR DEVELOPMENT AGREEMENTS AND CLINICAL INVESTIGATIONS.—

(i) IN GENERAL.—In the case of information submitted under subsection (a) with respect to a payment or other transfer of value made to a covered recipient by an applicable manufacturer pursuant to a product research or development agreement for services furnished in connection with research on a potential new medical technology or a new application of an existing medical technology or the development of a new drug, device, biological, or medical supply, or by an applicable manufacturer in connection with a clinical investigation regarding a new drug, device, biological, or medical supply, the procedures established under subparagraph (A)(ii) shall provide that such information is made available to the public on the first date described in the matter preceding clause (i) in subparagraph (C) after the earlier of the following:

(I) The date of the approval or clearance of the covered drug, device, biological, or medical supply by the Food and Drug Administration.

(II) Four calendar years after the date such payment or other transfer of value was made.

(ii) CONFIDENTIALITY OF INFORMATION PRIOR TO PUBLICATION.—Information described in clause (i) shall be considered confidential and shall not be subject to disclosure under section 552 of title 5, United States Code, or any other similar Federal, State, or local law, until on or after the date on which the information is made available to the public under such clause.

(2) CONSULTATION.—In establishing the procedures under paragraph (1), the Secretary shall consult with the Inspector General of the Department of Health and Human Services, affected industry, consumers, consumer advocates, and other interested parties in order to ensure that the information made available to the public under such paragraph is presented in the appropriate overall context.

(d) ANNUAL REPORTS AND RELATION TO STATE LAWS.—

(1) ANNUAL REPORT TO CONGRESS.—Not later than April 1 of each year beginning with 2013, the Secretary shall submit to Congress a report that includes the following:

(A) The information submitted under subsection (a) during the preceding year, aggregated for each applicable manufacturer and applicable group purchasing organization that submitted such information during such year (except, in the case of information submitted with respect to a payment or other transfer of value described in subsection (c)(1)(E)(i), such information shall be included in the first report submitted to

Congress after the date on which such information is made available to the public under such subsection).

(B) A description of any enforcement actions taken to carry out this section, including any penalties imposed under subsection (b), during the preceding year.

(2) ANNUAL REPORTS TO STATES.—Not later than September 30, 2013, and on June 30 of each calendar year thereafter, the Secretary shall submit to States a report that includes a summary of the information submitted under subsection (a) during the preceding year with respect to covered recipients in the State (except, in the case of information submitted with respect to a payment or other transfer of value described in subsection (c)(1)(E)(i), such information shall be included in the first report submitted to States after the date on which such information is made available to the public under such subsection).

(3) RELATION TO STATE LAWS.—

(A) IN GENERAL.—In the case of a payment or other transfer of value provided by an applicable manufacturer that is received by a covered recipient (as defined in subsection (e)) on or after January 1, 2012, subject to subparagraph (B), the provisions of this section shall preempt any statute or regulation of a State or of a political subdivision of a State that requires an applicable manufacturer (as so defined) to disclose or report, in any format, the type of information (as described in subsection (a)) regarding such payment or other transfer of value.

(B) NO PREEMPTION OF ADDITIONAL REQUIREMENTS.—Subparagraph (A) shall not preempt any statute or regulation of a State or of a political subdivision of a State that requires the disclosure or reporting of information—

(i) not of the type required to be disclosed or reported under this section;

(ii) described in subsection (e)(10)(B), except in the case of information described in clause (i) of such subsection;

(iii) by any person or entity other than an applicable manufacturer (as so defined) or a covered recipient (as defined in subsection (e)); or

(iv) to a Federal, State, or local governmental agency for public health surveillance, investigation, or other public health purposes or health oversight purposes.

(C) Nothing in subparagraph (A) shall be construed to limit the discovery or admissibility of information described in such subparagraph in a criminal, civil, or administrative proceeding.

(4) CONSULTATION.—The Secretary shall consult with the Inspector General of the Department of Health and Human Services on the implementation of this section.

(e) DEFINITIONS.—In this section:

(1) APPLICABLE GROUP PURCHASING ORGANIZATION.—The term “applicable group purchasing organization” means a group purchasing organization (as defined by the Secretary) that purchases, arranges for, or negotiates the purchase of a covered drug,

device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States.

(2) APPLICABLE MANUFACTURER.—The term “applicable manufacturer” means a manufacturer of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States.

(3) CLINICAL INVESTIGATION.—The term “clinical investigation” means any experiment involving 1 or more human subjects, or materials derived from human subjects, in which a drug or device is administered, dispensed, or used.

(4) COVERED DEVICE.—The term “covered device” means any device for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan).

(5) COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLY.—The term “covered drug, device, biological, or medical supply” means any drug, biological product, device, or medical supply for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan).

(6) COVERED RECIPIENT.—

(A) IN GENERAL.—Except as provided in subparagraph (B), the term “covered recipient” means the following:

(i) A physician.

(ii) A teaching hospital.

(B) EXCLUSION.—Such term does not include a physician who is an employee of the applicable manufacturer that is required to submit information under subsection (a).

(7) EMPLOYEE.—The term “employee” has the meaning given such term in section 1877(h)(2).

(8) KNOWINGLY.—The term “knowingly” has the meaning given such term in section 3729(b) of title 31, United States Code.

(9) MANUFACTURER OF A COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLY.—The term “manufacturer of a covered drug, device, biological, or medical supply” means any entity which is engaged in the production, preparation, propagation, compounding, or conversion of a covered drug, device, biological, or medical supply (or any entity under common ownership with such entity which provides assistance or support to such entity with respect to the production, preparation, propagation, compounding, conversion, marketing, promotion, sale, or distribution of a covered drug, device, biological, or medical supply).

(10) PAYMENT OR OTHER TRANSFER OF VALUE.—

(A) IN GENERAL.—The term “payment or other transfer of value” means a transfer of anything of value. Such term does not include a transfer of anything of value that is

made indirectly to a covered recipient through a third party in connection with an activity or service in the case where the applicable manufacturer is unaware of the identity of the covered recipient.

(B) EXCLUSIONS.—An applicable manufacturer shall not be required to submit information under subsection (a) with respect to the following:

- (i) A transfer of anything the value of which is less than \$10, unless the aggregate amount transferred to, requested by, or designated on behalf of the covered recipient by the applicable manufacturer during the calendar year exceeds \$100. For calendar years after 2012, the dollar amounts specified in the preceding sentence shall be increased by the same percentage as the percentage increase in the consumer price index for all urban consumers (all items; U.S. city average) for the 12-month period ending with June of the previous year.
 - (ii) Product samples that are not intended to be sold and are intended for patient use.
 - (iii) Educational materials that directly benefit patients or are intended for patient use.
 - (iv) The loan of a covered device for a short term trial period, not to exceed 90 days, to permit evaluation of the covered device by the covered recipient.
 - (v) Items or services provided under a contractual warranty, including the replacement of a covered device, where the terms of the warranty are set forth in the purchase or lease agreement for the covered device.
 - (vi) A transfer of anything of value to a covered recipient when the covered recipient is a patient and not acting in the professional capacity of a covered recipient.
 - (vii) Discounts (including rebates).
 - (viii) In-kind items used for the provision of charity care.
 - (ix) A dividend or other profit distribution from, or ownership or investment interest in, a publicly traded security and mutual fund (as described in section 1877(c)).
 - (x) In the case of an applicable manufacturer who offers a self-insured plan, payments for the provision of health care to employees under the plan.
 - (xi) In the case of a covered recipient who is a licensed non-medical professional, a transfer of anything of value to the covered recipient if the transfer is payment solely for the non-medical professional services of such licensed non-medical professional.
 - (xii) In the case of a covered recipient who is a physician, a transfer of anything of value to the covered recipient if the transfer is payment solely for the services of the covered recipient with respect to a civil or criminal action or an administrative proceeding.
- (11) PHYSICIAN.—The term “physician” has the meaning given that term in section 1861(r).

Appendix B. Aggregate Data by Applicable Manufacturer/Group Purchasing Organization (Identified Data).

The aggregated data included in this report (Appendix B) contains only **identified data** from Program Year 2013. This data set has been verified to have congruent identifying information about the covered recipient and has undergone review and dispute for 45-days as per the final rule. As a result, we have confidence in the accuracy of the data provided in this Report to Congress. Data that was found to have inconsistencies regarding the covered recipient of the payment or other transfer of value are not included in this report since those data have been returned to the reporting applicable manufacturers and GPOs for correction and resubmission. CMS will publish a complete, identified dataset for Program Year 2013 at the same time Program Year 2014 data is published in June, 2015.

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
.DECIMAL	\$1,254				1				1	0
3M COMPANY	\$437,863	\$48,060			2,820	5			2,119	2
4WEB, INC.	\$4,800	\$25,000	\$524,991	\$1,403,067	24	1	4	4	22	1
AAREN SCIENTIFIC INC.	\$782				2				2	0
ABB CON-CISE OPTICAL GROUP LLC	\$20,388				648				517	0
ABBOTT LABORATORIES	\$2,830,143	\$440,573			8,922	137			4,657	85
ABBVIE, INC.	\$8,034,886	\$669,998			66,598	86			27,315	64
ABEON MEDICAL CORPORATION	\$916				1				1	0
ABIOMED	\$249,068	\$305,279			1,016	55			607	18
ABL MEDICAL, LLC	\$31,581				36				35	1
ACCEL SPINE, LLC	\$17,961				20				12	0
ACCESS CLOSURE, INC	\$13,879	\$8,439	\$3,101,323	\$1,766,962	420	5	41	41	456	0
ACCLARENT, INC	\$446,602	\$9,069			3,379	5			1,685	2
ACCURAY INCORPORATED	\$59,083	\$704,510			108	9			52	10
ACE SURGICAL SUPPLY CO., INC.	\$4,777				30				23	0
ACORDA THERAPEUTICS, INC	\$1,025,927	\$738,877			1,297	10			283	9
ACTAVIS PHARMA INC	\$820,098	\$62,431			11,094	10			5,250	7
ACTELION CLINICAL RESEARCH, INC.	\$11,788	\$520,143			9	181			53	0
ACTELION PHARMACEUTICALS US, INC.	\$801,014	\$1,180,653			6,541	80			3,776	12
ACTELION PHARMACEUTICALS, LTD	\$161,627	\$202,688			118	25			37	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
ACTIVE MEDICAL, LLC	\$682				3				3	0
ACUMED LLC	\$1,168,521				690				364	3
ACUTE INNOVATIONS, LLC	\$1,445				8				7	0
A-DEC, INC.	\$222,400				1,300				694	3
ADVANCED BIONICS, LLC	\$239,666	\$5,675			60	5			31	6
ADVANCED CIRCULATORY SYSTEMS INC.	\$3,422	\$14,812	\$1,296,608	\$2,490,002	24	2	8	8	24	1
ADVANCED CRITICAL DEVICES, INC.	\$814				20				14	0
ADVANCED MEDICAL PARTNERS INC	\$2,464				66				48	0
ADVANCED ORTHOPAEDIC SOLUTIONS, INC.	\$83,912				28				27	0
ADVANCED RESPIRATORY, INC	\$38,641				878				627	22
AEGERION PHARMACEUTICALS, INC.	\$251,189		\$415,385	\$1,920,962	1,354		3	3	910	2
AEROCRINE, INC	\$72,050				555				403	0
AERO-MED LTD	\$11,800				2				0	1
AESULAP AG	\$16,734				15				7	0
AESULAP AKADEMIE GMBH	\$12,744				11				4	0
AESULAP BIOLOGICS, LLC	\$9,078				13				7	0
AESULAP IMPLANT SYSTEMS, LLC	\$193,676				230				91	3
AESULAP, INC.	\$75,021				236				121	47
AFAXYS, INC.	\$5,214				14				6	0
AFFORDABLE PHARMACEUTICALS, LLC	\$159,263				4				2	0
AGFA HEALTHCARE CORPORATION	\$245,248				51				25	10

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
AKORN INC.	\$505				21				19	0
AKRIMAX PHARMACEUTICALS, LLC	\$92,116				1,316				790	0
ALCON LABORATORIES INC	\$4,627,611				23,051				8,428	3
ALCON PHARMACEUTICALS LTD	\$381,320				4				3	0
ALCON PUERTO RICO INC	\$9,118				34				25	0
ALCON RESEARCH LTD	\$1,065,972	\$1,160,704			473	557			276	15
ALDEN OPTICAL LABORATORIES, INC	\$20,110				9				5	0
ALERE HOME MONITORING, INC.	\$80,342				4				2	0
ALERE INFORMATICS, INC.	\$39,080				10				5	0
ALERE NORTH AMERICA, LLC	\$3,987				71				69	0
ALERE SAN DIEGO, INC.	\$110,821	\$39,815			12	7			9	3
ALEXION PHARMACEUTICALS, INC.	\$1,156,839	\$472,708			4,619	61			2,067	45
ALEXZA PHARMACEUTICALS, INC.	\$590	\$4,400	\$3,199	\$20,124	1	1	2	2	3	0
ALGETA US LLC	\$121,554	\$15,016			1,123	7			851	6
ALK-ABELLO, INC	\$33,692				101				71	0
ALKERMES, INC.	\$301,371	\$19,337			2,382	11			1,175	4
ALLERDERM LABORATORIES	\$5,936				6				6	0
ALLERGAN INC.	\$12,306,126	\$3,057,405			81,377	652			24,821	58
ALLIQUA BIOMEDICAL, INC.	\$1,071				20				19	0
ALLOSOURCE	\$687				35				31	0
ALPHA ORTHOPEDIC SYSTEMS	\$6,674				78				47	0
ALPHATEC SPINE, INC	\$891,743	\$125,876			272	33			99	1
ALPINE SURGICAL TECHNOLOGIES, LLC			\$10,982	\$10,982			5	5	3	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
ALTATEC GMBH	\$55,500				94				57	0
AMAG PHARMACEUTICALS, INC.	\$126,053	\$13,256			898	3			667	0
AMARIN PHARMA INC.	\$1,259,114	\$26,026			7,446	8			4,346	3
AMD LASERS LLC	\$14,298				24				11	0
AMEDICA CORPORATION	\$338,159		\$5,253,767	\$593,749	93		44	44	86	0
AMENDIA, INC.	\$696,428		\$4,040,700	\$7,697,166	215		11	11	47	0
AMERICAN MEDICAL HOSPITAL SUPPLY COMPANY, INC.	\$4,116				34				12	0
AMERICAN MEDICAL SYSTEMS INC.	\$1,085,588	\$18,164			4,434	25			1,759	3
AMERICAN MEDICAL TECHNOLOGY INC	\$531				2				1	1
AMERICAN ORTHODONTICS CORPORATION	\$23,487				59				59	0
AMGEN INC.	\$6,729,907	\$1,308,023			40,943	717			18,843	110
AMNIOX MEDICAL	\$154,317				393				180	0
AMPHASTAR PHARMACEUTICALS, INC.			\$3,569,415	\$13,940,920			8	8	8	0
ANALOGIC CORPORATION	\$1,619				34				34	0
ANESTHETIC GAS RECLAMATION, LLC			\$445,001	\$615,000			3	3	3	0
ANGIODYNAMICS, INC.	\$552,562	\$5,000			923	1			894	2
ANGIOSCORE, INC.	\$124,949				1,147				720	2
ANIKA THERAPEUTICS, INC.	\$12,787				13				11	0
ANIMAS CORPORATION	\$71,769				1,520				725	23
ANSELL HEALTHCARE PRODUCTS LLC		\$66,640				6			1	0
APOLLO SURGICAL GROUP, LLC	\$25,625				96				66	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
APO-PHARMA INC.	\$85,366	\$67,443			52	3			32	2
APPLIED MEDICAL AUSTRALIA	\$3,149				1				1	0
APPLIED MEDICAL CORPORATION			\$1,289,747	\$8,731,279			28	28	24	0
APPLIED MEDICAL EUROPE BV	\$9,044				7				2	0
APPLIED MEDICAL RESOURCES CORPORATION	\$160,840				252				112	6
APPLIED MEDICAL TECHNOLOGY INC	\$7,095				28				9	5
APTALIS PHARMA US, INC.	\$700,295				10,773				3,334	11
APTIS MEDICAL, LLC	\$2,882				3				2	0
AQUESYS, INC.			\$10	\$4,540			1	1	1	0
ARBOR PHARMACEUTICALS, INC.	\$160,191				3,280				2,264	0
ARGON MEDICAL DEVICES, INC.	\$23,410	\$25,000			413	1			246	0
ARIAD PHARMACEUTICALS, INC.	\$346,346	\$1,023,817			903	169			600	25
ARIOSIA DIAGNOSTICS, INC.	\$6,193				78				76	0
ARIZONA CRYOSURGICAL PARTNERSHIP LP	\$65,246		\$394,557	\$259,611	74		15	15	15	0
ARJOHUNTLEIGH, INC.	\$4,479				64				62	0
ARROW INTERNATIONAL, INC.	\$1,152				9				4	0
ART OPTICAL CONTACT LENS INC.	\$11,529				34				18	0
ARTERIOCYTE MEDICAL SYSTEMS, INC.	\$45,509		\$3,150	\$3,150	22		1	1	22	0
ARTHREX, INC.	\$15,539,935	\$4,700			3,364	3			1,019	2
ARTHROCARE CORPORATION	\$220,286				579				365	1
ARTHROSURFACE INCORPORATED	\$86,447	\$2,850	\$3,478,797	\$6,619,206	417	1	30	30	403	0
ASAHI INTECC CO., LTD.	\$11,167				5				3	0
ASAHI INTECC USA, INC.	\$55,007				62				30	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
ASCEND THERAPEUTICS US, LLC	\$35,036	\$3,296			1,625	1			464	0
ASCENSION ORTHOPEDICS, INC.	\$75,653	\$888			169	2			60	0
ASEPTICO, INC.	\$8,750				1				1	0
ASTELLAS PHARMA EUROPE BV	\$20,700				51				23	0
ASTELLAS PHARMA GLOBAL DEVELOPMENT	\$202,917	\$24,896			62	8			18	6
ASTELLAS PHARMA INC	\$14,187	\$61,471			18	16			15	7
ASTELLAS PHARMA US INC	\$1,512,596				28,651				13,645	50
ASTELLAS SCIENTIFIC AND MEDICAL AFFAIRS	\$6,421	\$140,486			31	26			45	2
ASTELLAS US TECHNOLOGIES		\$3,013				3			0	2
ASTRAZENECA AB	\$16,391	\$649			2	1			2	1
ASTRAZENECA PHARMACEUTICALS LP	\$15,110,111	\$2,090,760			161,669	138			57,772	161
ASTRAZENECA UK LIMITED	\$34,047	\$9,280			32	6			16	4
ASURAGEN, INC.	\$3,864				58				55	1
ATLANTIC COAST CRYOTHERAPY LP	\$83,503		\$224,137	\$227,804	135		28	28	27	0
ATLAS SPINE, INC.	\$500		\$75,000	\$150,000	1		2	2	3	0
ATOS MEDICAL INC	\$993				35				35	0
ATOSSA GENETICS INC	\$2,663				24				24	0
ATRICURE, INC.	\$692,115	\$94,012			1,529	16			763	12
ATRIUM MEDICAL CORPORATION	\$128,526	\$74,955			1,231	27			929	1
AUXILIUM PHARMACEUTICALS, INC.	\$1,593,923	\$19,185			17,960	13			7,900	4
AVANIR PHARMACEUTICALS, INC.	\$1,704,567	\$19,642			8,740	2			3,309	2
AVID RADIOPHARMACEUTICALS, INC.	\$61,492	\$333,216			29	16			11	7

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
AVINGER INC.	\$76,917	\$5,000	\$24,979,281	\$24,979,281	651	2	22	22	275	1
AVION PHARMACEUTICALS	\$6,961				218				169	0
AXOGEN	\$213,545	\$13,990	\$424,074	\$1,264,967	569	6	3	3	284	3
B. BRAUN INTERVENTIONAL SYSTEMS INC.	\$22,157	\$10,063			63	2			45	5
B. BRAUN MEDICAL INC.	\$108,193	\$19,839			75	2			48	18
B. BRAUN SURGICAL SA	\$4,382				4				1	0
B2D MARKETING	\$660				13				12	0
BACTERIN INTERNATIONAL INC	\$121,719	\$10,000	\$213,974	\$97,161	140	1	11	11	110	0
BANYAN INTERNATIONAL CORPORATION	\$108				2				1	0
BARD ACCESS SYSTEMS, INC.	\$109,574	\$7,200			601	5			558	12
BARD INTERNATIONAL, INC.	\$87,492				64				41	0
BARD PERIPHERAL VASCULAR, INC.	\$1,521,667	\$78,524			3,949	47			2,021	16
BAUSCH AND LOMB INC.	\$1,984,583	\$1,526,100			12,992	203			6,168	8
BAXANO SURGICAL, INC.	\$299,915				942				370	0
BAXTER HEALTHCARE	\$933,587	\$150,000			3,522	1			2,374	7
BAYER HEALTHCARE LLC	\$21,725				836				558	3
BAYER HEALTHCARE PHARMACEUTICALS INC.	\$1,220,088	\$262,228			5,931	37			3,522	33
BAYLIS MEDICAL COMPANY INC	\$2,799				1				1	0
BD RX INC.	\$22				2				2	0
BEACON ENDOSCOPIC CORPORATION	\$9,494		\$868,918	\$652,921	38		14	14	32	0
BEAVER-VISITEC INTERNATIONAL, INC.	\$18,645	\$7,400			34	3			29	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
BECKMAN COULTER, INC.	\$17,297				94				6	36
BECTON, DICKINSON AND COMPANY	\$2,579,918	\$393,295			1,156	26			813	61
BELMONT INSTRUMENT CORPORATION	\$11,926				3				1	1
BENCO DENTAL SUPPLY CO.	\$924,289				7,590				1,249	0
BENVENUE MEDICAL INC	\$89,748	\$11,500			77	3			16	1
BG MEDICINE, INC.	\$57,574				58				26	0
BIO PRODUCTS LABORATORY, INC.	\$481	\$28,022			10	5			10	0
BIOCOMPATIBLES UK LTD	\$65,894				8				4	1
BIOCOMPATIBLES, INC.	\$64,841				211				156	0
BIOCOMPOSITES INC	\$215,653				132				108	0
BIO-DETEK INC.	\$25				1				1	0
BIOFIRE DIAGNOSTICS, LLC	\$33,217	\$73,747			10	4			3	10
BIOGEN IDEC INC.	\$1,682,549	\$808,573			8,876	189			1,399	34
BIOHORIZONS IMPLANT SYSTEMS, INC.	\$1,029,475		\$609,942	\$1,053,959	2,163		22	22	1,182	5
BIOLASE, INC.	\$281,082	\$45,000			583	1			241	0
BIOMARIN PHARMACEUTICAL INC.	\$52,421	\$105,653			93	18			43	6
BIOMERIEUX	\$60,103	\$8,750			88	3			69	1
BIOMET 3I CANADA INC	\$201				4				1	0
BIOMET 3I DEUTSCHLAND GMBH	\$8,244				1				1	0
BIOMET 3I MEXICO SA DE CV	\$605				2				2	0
BIOMET 3I UK LTD	\$44				1				1	0
BIOMET 3I, LLC	\$1,164,323				4,061				2,397	5
BIOMET BIOLOGICS, LLC	\$19,109	\$140,444			67	10			55	3

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
BIOMET EUROPE, LTD	\$33,307				40				11	0
BIOMET INTERNATIONAL, LTD	\$294,423				48				16	0
BIOMET MICROFIXATION, LLC	\$859,121	\$22,031			751	8			430	6
BIOMET ORTHOPEDICS, LLC	\$7,994,586	\$65,361			3,222	18			983	77
BIOMET SPINE, LLC	\$1,705,667	\$1,500			605	1			326	6
BIOMET SPORTS MEDICINE, LLC	\$668,663				526				251	1
BIOMET TRAUMA, LLC	\$1,237,535				962				357	0
BIOMIMETIC THERAPEUTICS, LLC	\$31,355	\$22,157			20	1			8	0
BIONESS INC	\$750	\$28,057	\$868	\$868	1	5	1	1	4	3
BIOPRO, INC.	\$15,230				16				8	0
BIO-RAD LABORATORIES, INC.	\$552,150	\$75,184			1,201	10			44	107
BIOSENSE WEBSTER, INC.	\$1,274,468	\$421,917			2,719	37			696	40
BIOTEST PHARMACEUTICALS CORPORATION	\$260				12				12	0
BIOTRONIK INC.	\$508,585	\$1,036,211			3,229	2,303			889	1
BIOVENTUS LLC	\$240,721				3,223				1,960	2
BLOCKADE MEDICAL, LLC	\$2,604		\$1,014,232	\$1,014,232	42		15	15	30	0
BLUE BELT TECHNOLOGIES, INC.	\$190,310		\$290,598	\$1,784,294	147		3	3	64	0
BLUE SKY BIO, LLC			\$25,000	\$25,000			1	1	1	0
BOEHRINGER INGELHEIM B.V.	\$93,141				65				18	0
BOEHRINGER INGELHEIM CANADA LTD.LTEE		\$39				1			1	0
BOEHRINGER INGELHEIM FRANCE	\$34				1				1	0
BOEHRINGER INGELHEIM HONG KONG LTD	\$9,167				4				1	0
BOEHRINGER INGELHEIM INTERNATIONAL GMBH	\$259,531	\$60,000			66	2			25	1

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
BOEHRINGER INGELHEIM LTDA	\$9,500				1				1	0
BOEHRINGER INGELHEIM MALAYSIA SDN. BHD.	\$5,301				2				2	0
BOEHRINGER INGELHEIM MEXICO SA DE CV	\$28,941				14				5	0
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG	\$773,028	\$3,500			250	1			66	0
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	\$7,786,846	\$103,429			102,657	20			39,025	31
BOEHRINGER INGELHEIM PTY LTD	\$23,642				9				2	0
BOEHRINGER INGELHEIM RCV GMBH & CO KG	\$22,348				4				2	0
BOEHRINGER INGELHEIM TAIWAN LTD.	\$9,430				3				1	0
BOEHRINGER INGELHEIM THAI LTD	\$13,763				8				1	0
BOLTON MEDICAL INC	\$31,728				182				73	0
BOSTON SCIENTIFIC CORPORATION	\$8,745,435	\$532,788			26,321	186			10,387	139
BRAEMAR MANUFACTURING, LLC	\$195,064		\$748,395	\$748,395	1,297		2	2	1,241	0
BRAHMS GMBH	\$2,633	\$20,675			3	3			2	1
BRAINLAB, INC.	\$101,304				523				290	3
BRAINTREE LABORATORIES, INC.	\$1,909,134	\$12,500	\$90,285,037	\$85,020,000	2,862	1	3	3	2,017	0
BRISTOL-MYERS SQUIBB COMPANY	\$8,451				3				2	0
BSD MEDICAL CORPORATION	\$11,851				8				8	0
BTG INTERNATIONAL CANADA INC.	\$152,224				131				60	2
BTG INTERNATIONAL, INC.	\$289,745				296				243	5

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
BUFFALO FILTER, LLC	\$935				47				47	0
C. R. BARD FOUNDATION, INC.	\$8,500				2				0	2
C. R. BARD, INC. & SUBSIDIARIES	\$446,046	\$103,801			583	4			379	26
CADENCE PHARMACEUTICALS, INC.	\$542,243	\$168,316			4,759	18			3,503	43
CADWELL INDUSTRIES, INC	\$7,514				10				9	0
CALDERA MEDICAL, INC	\$21,898				24				18	0
CANTEL MEDICAL CORP.		\$17,322				1			0	1
CAPITOL CRYOTHERAPY LP	\$68,275		\$191,794	\$216,520	40		8	8	8	0
CAPTIVA SPINE INC	\$76,047				24				14	0
CARACO PHARMACEUTICAL LABORATORIES, LTD.	\$150,350				5				1	0
CARDIAC ASSIST, INC.		\$32,979				2			0	1
CARDICA, INC.	\$1,269	\$39,909	\$25,800	\$25,800	13	5	1	1	10	3
CARDINAL HEALTH 108, LLC	\$174,422				647				102	0
CARDINAL HEALTH 110, LLC	\$10,288				3				1	1
CARDINAL HEALTH 200, LLC	\$80,662				115				97	2
CARDINAL HEALTH 414, LLC	\$106,694				476				82	0
CARDINAL HEALTH P.R. 120, INC.	\$148				5				5	0
CARDIOSOLUTIONS, INC.	\$29,501		\$1,084,635	\$1,309,202	5		25	25	25	0
CARDIOVASCULAR SYSTEMS INC.	\$938,091	\$44,496	\$289,242	\$628,673	5,447	28	1	1	2,267	8
CARDIVA MEDICAL, INC.	\$10,196				42				42	0
CAREFUSION CORPORATION	\$571,518	\$377,063	\$0	\$1,187,751	827	2	1	1	251	216
CARESTREAM DENTAL, LLC	\$376,343				1,178				890	0
CARESTREAM HEALTH, INC.	\$41,241	\$100,000			24	1			10	2
CARL ZEISS MEDITEC, INC.	\$345,200				519				327	15

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
CARTER BLOODCARE	\$152,998				56				7	3
CAS MEDICAL SYSTEMS INC.	\$37,109				48				38	1
CATHETER ROBOTICS INC.		\$29,792				2			0	2
CCPA PURCHASING PARTNERS, L.P.			\$5,406	\$74,976			170	170	169	0
CDC MEDICAL LLC	\$7,014				17				14	0
CELGENE CORPORATION	\$3,438,259	\$2,822,086			12,474	358			4,281	72
CELLERATION_INC	\$6,429	\$10,980			55	7			45	3
CELONOVA BIOSCIENCES, INC.	\$135,824	\$400	\$0	\$0	12	1	7	7	13	0
CENTINEL SPINE, INC.	\$104,499	\$10,600	\$0	\$261,116	124	1	8	8	83	0
CENTRAL BLOOD BANK	\$11,403				15				1	2
CENTRAL CALIFORNIA SURGICAL DISTRIBUTORS, LLC			\$53,638	\$53,638			5	5	3	0
CENTRAL DALLAS SURGICAL SUPPLY, LLC			\$100,000	\$100,000			4	4	4	0
CEPHEID	\$1,237,431				94				21	13
CEPTARIS THERAPEUTICS, INC.	\$5,505				10				10	0
CEREXA, INC.	\$31,963	\$33,381			17	26			4	26
CETERIX ORTHOPAEDICS, INC.		\$42,252				1			0	1
CHEETAH MEDICAL, INC.	\$6,928				17				16	1
CHUGAI PHARMACEUTICAL CO., LTD.	\$100,827				40				18	0
CLARIANCE, INC.	\$6,722				10				4	0
CLARITY MEDICAL SYSTEM	\$73,789				32				10	0
CLINICAL TECHNOLOGY, INC	\$144				11				10	0
CLINICIAN'S CHOICE DENTAL PRODUCTS INC.	\$16,263				23				5	0
COALIGN INNOVATIONS, INC.	\$839		\$50,000	\$109,667	10		2	2	9	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
COCHLEAR AMERICAS	\$260,612	\$70,877			687	58			307	47
COCHLEAR HK LTD	\$8,041				2				1	0
COCHLEAR LTD	\$16,869				18				11	0
COCHLEAR MEDICAL DEVICE BEIJING CO LTD	\$5,442				1				1	0
CODMAN & SHURTLEFF INC.	\$220				2				2	0
COLLAGEN MATRIX, INC	\$58				3				3	0
COLOPLAST CORP	\$760,139	\$54,445			3,190	30			1,347	22
COMMUNITY BLOOD CENTER	\$17				1				1	0
COMSORT, INC	\$131,700				1,460				1,450	0
CONFORMIS, INC.	\$756,670	\$135,136	\$1,033,329	\$11,722,492	482	3	14	14	232	6
CONMED CORPORATION	\$235,023				386				316	4
CONSENSUS ORTHOPEDICS, INC.	\$60,686		\$951,841	\$1,092,705	156		9	9	28	0
CONVATEC INC.	\$77,271				645				553	35
CONVERGENT DENTAL INC.	\$29,822		\$2,087,500	\$3,056,859	38		14	14	23	0
COOK INCORPORATED	\$3,683,563				5,394				2,874	4
COOK MEDICAL LLC	\$32,352				111				86	0
COOK MEDICAL TECHNOLOGIES LLC	\$5,023				3				3	0
COOPERSURGICAL, INC.	\$465,489				183				140	0
COOPERVISION INC.	\$300,076				3,719				2,636	0
CORCEPT THERAPEUTICS	\$132,687				547				293	0
CORDIS CORPORATION	\$352,403	\$265,565			2,898	53			1,156	48
CORELINK, LLC	\$8,608		\$140,000	\$110,588	12		2	2	10	0
CORMATRIX CARDIOVASCULAR INC.	\$166,950	\$20,209	\$405,122	\$1,694,956	854	4	5	5	395	3

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
CORNERSTONE THERAPEUTICS INC.	\$235,972				1,051				601	29
COSMEDENT, INC.	\$40,047		\$40,000	\$100,000	15		1	1	6	0
COTHERIX, INC.		\$14,301				9			9	0
COVIDIEN LP	\$2,888,766	\$558,342			3,605	184			1,908	70
COVIDIEN SALES LLC	\$2,914,855				12,090				6,552	116
COVIS PHARMACEUTICALS, INC.	\$19				1				1	0
CROSTEX INTERNATIONAL INC.	\$722				3				2	0
CRYO SPECIALTY MEDICAL, LLC	\$144,174		\$463,506	\$819,990	970		195	195	193	0
CRYO VENTURES 6, LLC	\$15,952		\$15,000	\$13,852	4		2	2	2	0
CRYOLIFE, INC.	\$170,934	\$19,371			1,153	3			539	5
CSA MEDICAL, INC	\$84,924	\$2,500	\$130,714	\$0	53	1	3	3	41	1
CSL BEHRING	\$925,550	\$8,225			4,556	4			2,524	2
CUBIST PHARMACEUTICALS INC	\$1,318,028	\$53,120			6,720	6			3,970	8
CUMBERLAND PHARMACEUTICALS, INC.	\$101,029	\$138,813			1,619	21			937	9
CUREXO TECHNOLOGY CORPORATION	\$36,924				2				2	0
CVRX, INC.	\$91,595		\$214,030	\$125,012	80		5	5	35	0
CYBERONICS, INC.	\$755,030	\$12,154			3,522	2			1,415	4
CYTORI THERAPEUTICS, INC.	\$6,332				12				4	0
D4D TECHNOLOGIES, LLC	\$40,793				178				178	0
DAIICHI SANKYO COMPANY LTD	\$34,950				19				10	1
DAIICHI SANKYO INC.	\$1,514,225	\$1,130,440			73,589	981			22,857	45
DAINIPPON SUNITOMO PHARMA CO LTD	\$38,218				20				10	0
DAKO NORTH AMERICA, INC	\$42,306				9				2	2

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
DAKOTA SCIENCES, LLC		\$6,400				1			1	0
DARBY DENTAL SUPPLY, LLC	\$63,958				2				2	0
DASH MEDICAL GLOVES INC	\$11,019				507				505	0
DATASCOPE CORP.	\$40,103	\$14,115			25	1			8	1
DAVOL INC.	\$1,974,354	\$18,750			3,168	1			1,723	11
DENDREON CORPORATION	\$745,442	\$279,345			5,061	170			2,481	46
DEN-MAT HOLDINGS, LLC	\$75,971				56				31	0
DENTAL EQUIPMENT LLC	\$50,689				244				101	0
DENTAL HEALTH PRODUCTS, INC.	\$227				2				2	0
DENTAL IMAGING TECHNOLOGIES CORP.	\$60,959				89				29	0
DENTAL MATERIAL GESELLSCHAFT MBH	\$386				6				3	0
DENTALEZ ALABAMA, INC.	\$56,716				5				4	0
DENTALEZ, INC.	\$75,916				171				85	0
DENTAURUM INCORPORATED	\$9,697				6				2	0
DENTPSLY IH AB	\$5,011	\$98,382			3	9			5	2
DENTSPLY CANADA LTD	\$18				1				1	0
DENTSPLY IH INC.	\$424,801				2,800				1,732	0
DENTSPLY INTERNATIONAL	\$126,259				1,522				1,329	2
DENTSPLY LLC	\$290,648	\$9,935			266	1			140	7
DENTSPLY US PROSTHETICS LLC	\$25,613				58				38	0
DEPOMED, INC.	\$426,856				4,499				2,396	0
DEPUY INSTITUTE, LLC	\$134				4				4	0
DEPUY MITEK LLC	\$2,907,649	\$3,000			29	1			13	1
DEPUY ORTHOPAEDICS INC.	\$6,411,589	\$631,222			3,677	24			1,018	102

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
DEPUY PRODUCTS INC.	\$619				10				8	0
DEPUY SPINE, LLC	\$206	\$3,500			2	1			2	1
DEPUY SYNTHES PRODUCTS LLC	\$26,954,533	\$77,710			628	1			201	3
DEPUY SYNTHES SALES INC.	\$1,219,433				12,299				4,711	15
DERMA SCIENCES, INC.	\$11,576				8				6	0
DERMARITE INDUSTRIES, LLC	\$24				2				2	0
DESERT MOUNTAIN MEDICAL	\$19,977				160				56	0
DEVICOR MEDICAL PRODUCTS, INC.	\$27,380		\$1	\$7,000	336		1	1	281	0
DEXCOM, INC.	\$33,227				555				296	0
DFINE, INC	\$146,160		\$30,900	\$1,495	937		1	1	586	1
DIADEXUS, INC.	\$61,557				683				573	0
DIAGNOSTICA STAGO SAS	\$14,980	\$77,975			2	1			2	1
DIAGNOSTICA STAGO, INC	\$8,243	\$16,266			38	4			11	3
DIGESTIVE CARE, INC.	\$845				35				32	0
DIGIRAD CORPORATION	\$1,871				37				32	0
DISCOVERY LABORATORIES, INC.	\$35,118				120				65	1
DJO GLOBAL, INC.	\$404,178				558				442	16
DMG AMERICA LLC	\$74,714				79				63	0
DOMAIN SURGICAL, INC.			\$1,555,400	\$1,556,600			13	13	13	0
DORNIER MEDTECH AMERICA, INC	\$1,735				20				19	0
DR.REDDY'S LABORATORIES,INC.	\$99,061				80				65	0
DS HEALTHCARE INC	\$3,454				171				169	0
DUCHESNAY INCORPORATED	\$27,841				8				1	0
DUCHESNAY USA INCORPORATED	\$152,538				1,845				1,192	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
DUSA PHARMACEUTICALS, INC.	\$174,968				2,065				1,222	0
DUX INDUSTRIES INC	\$14,367				10				10	0
DYAX CORP	\$121,973	\$10,375			587	1			297	1
DYNASPLINT SYSTEMS INC.	\$481				31				28	0
DYNATRONICS CORP.	\$75				2				2	0
E.R. SQUIBB & SONS, L.L.C.	\$6,329,012	\$22,026,337			57,903	233			25,910	150
EBI MEDICAL SYSTEMS, LLC	\$14,324	\$4,400			495	1			413	1
ECARDIO DIAGNOSTICS, LLC	\$53,445	\$10,000			29	1			19	4
ECKERT & ZIEGLER, BEBIG	\$238				2				2	0
ECR PHARMACEUTICALS CO., INC.	\$33,755				434				321	0
EDAP TECHNOMED INC	\$2,877				18				7	0
EDWARDS LIFESCIENCES CORPORATION	\$1,899,085	\$1,532,436			5,705	51			1,277	136
EISAI CO., LTD.	\$153	\$121,290			1	179			1	2
EISAI INC.	\$1,008,287	\$186,576			10,556	55			7,268	18
EKOS CORPORATION	\$268,875	\$3,000	\$54,000	\$54,000	619	1	3	3	420	26
ELECTROMED, INC.	\$11,683				384				340	5
ELEKTA LTD	\$87				5				1	0
ELEKTA MEDICAL, S.A.	\$2,575				1				1	0
ELEKTA OY	\$248				4				4	0
ELEKTA, INC.	\$194,019				484				249	6
ELI LILLY AND COMPANY	\$2,560,456	\$3,231,864			609	345			276	98
ELI LILLY EXPORT S.A. PUERTO RICO BRANCH	\$3,041				27				14	0
ELLEX, INC	\$24,457				56				41	0
ELLIPSE TECHNOLOGIES, INC.	\$105,895		\$2,870,053	\$2,870,053	49		15	15	24	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
ELLMAN INTERNATIONAL	\$140,162				85				75	0
EMD MILLIPORE CORPORATION	\$588,008				819				4	79
EMD SERONO, INC.	\$857,748	\$336,528			8,309	121			3,197	24
EMERGENT BIOSOLUTIONS INC.	\$27,305	\$7,480			166	2			103	5
EMINENT SPINE, LLC		\$2,100				1			1	0
EMPI, INC.	\$46,990				1,484				1,126	0
ENCISION INC	\$269				13				13	0
ENCORE MEDICAL, LP	\$762,059	\$15,115			684	5			254	3
END PRODUCT RESULTS LLC	\$21,000				4				1	0
ENDO PHARMACEUTICALS INC.	\$244,622	\$388,163			6,049	29			4,093	9
ENDOCARE, INC.	\$67,293				261				163	0
ENDOCHOICE, INC.	\$58,590		\$99,825	\$2,151,543	160		8	8	102	0
ENDOCO INC DBA ULTIMATE DENTAL	\$23,050				76				44	0
ENDOEVOLUTION, LLC	\$506,876				5				3	0
ENDOGASTRIC SOLUTIONS, INC	\$19,208	\$23,450	\$127,498	\$54,930	143	10	3	3	97	0
ENDOLOGIX, INC.	\$323,610				1,075				353	3
ENTELLUS MEDICAL, INC.	\$350,448	\$1,650	\$0	\$157,592	1,904	2	2	2	826	2
ENVOY MEDICAL CORPORATION	\$11,186				25				11	0
EPIMED INTERNATIONAL, INC	\$128,266				72				48	0
ERBE USA INC	\$11,300				25				19	5
ESAOTE NORTH AMERICA, INC.	\$13,702				27				10	0
ESSENTIAL DENTAL SYSTEMS INCORPORATED	\$7,301				169				128	0
ETEX CORPORATION	\$79,187				56				15	0
ETHICON ENDO-SURGERY INC.	\$721,629	\$73,863			1,489	3			1,064	25

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
ETHICON INC.	\$2,358,331	\$41,008			7,348	9			3,738	65
EVALVE INC.	\$110,232		\$3	\$0	3		3	3	3	0
EVERETT LABORATORIES, INC	\$33,203				366				266	0
EVERGREEN ORTHOPEDIC RESEARCH LAB LLC	\$56,321		\$164,462	\$72,394	23		1	1	5	0
EVOFEM INC.		\$2,653,928				73			36	0
EXACTA DENTAL PRODUCTS, INC.	\$7,241				160				110	0
EXACTECH, INC.	\$1,615,903	\$56,250			696	3			307	0
EXELIXIS INC.	\$573,547	\$590,278			417	82			345	27
EXTREMITY MEDICAL	\$119,368		\$0	\$1,228,095	88		5	5	42	0
F. HOFFMANN-LA ROCHE AG	\$405,935	\$86,616			262	3			118	2
FARALLON SURGICAL, LLC	\$20,000		\$15,000	\$395,401	1		1	1	2	0
FCI OPHTHALMICS, INC.	\$212				2				2	0
FERA PHARMACEUTICALS, LLC	\$784				3				3	0
FERRING INTERNATIONAL CENTER SA	\$8,620				12				6	0
FERRING INTERNATIONAL PHARMASCIENCE CENTER US	\$2,279				3				2	0
FERRING PHARMACEUTICALS AS	\$20,855				23				4	0
FERRING PHARMACEUTICALS INC.	\$902,954	\$9,450			11,115	1			5,610	5
FERRING PHARMACEUTICALS LLC	\$7,932				7				1	0
FERRING PHARMACEUTICALS LTD	\$18,836				11				1	0
FERRING RESEARCH INSTITUTE INC.	\$12,862				13				2	0
FERRING SA DE CV	\$3,074				2				1	0
FFF ENTERPRISES, INC.	\$10,000				4				4	0
FIDIA PHARMA USA INC	\$13,832				115				105	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
FISHER & PAYKEL HEALTHCARE INC	\$23,166				465				348	0
FISHER SCIENTIFIC COMPANY L.L.C.	\$8,609				61				54	0
FLEXUSPINE, INC	\$790				4				4	0
FLOWONIX MEDICAL INCORPORATED	\$56,982				127				127	0
FOREST LABORATORIES, INC.	\$453,793				49				16	0
FOREST PHARMACEUTICALS, INC.	\$9,884,908				125,036				37,689	16
FOREST RESEARCH INSTITUTE, INC.	\$75,983	\$1,423,017			96	122			79	24
FORT WORTH SURGICAL SUPPLY, LLC	\$98		\$50,000	\$50,000	1		1	1	1	0
FRESENIUS KABI USA, LLC	\$20,707				17				6	1
FRESENIUS USA INC.	\$2,151				2				2	0
FRESENIUS USA MARKETING, INC.	\$28,298	\$85,250			215	3			148	2
FSC LABORATORIES, INC.	\$1,567				162				144	0
FUJIFILM MEDICAL SYSTEMS USA, INC.	\$95,931				188				126	6
FUJIFILM SONOSITE, INC.	\$166,451				606				426	7
FUJIREBIO DIAGNOSTICS, INCORPORATED	\$787,400	\$213,345			4	8			1	10
FUKUDA DENSHI CO., LTD.	\$3,441				3				2	0
FUKUDA DENSHI USA, INC.	\$37				1				1	0
GAC INTERNATIONAL LLC	\$531,417				567				252	5
GALDERMA LABORATORIES, L.P.	\$807,214				7,681				3,065	0
GALDERMA RESEARCH & DEVELOPMENT, LLC	\$12,262	\$144,129			15	10			12	0
GALEN US INC	\$141				9				9	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
GALENA BIOPHARMA, INC.	\$44,454				334				334	0
GALIL MEDICAL INC.	\$69,052	\$13,570			67	19			36	23
GALT MEDICAL	\$2,596				14				7	0
GAMBRO AAB	\$465,769				1,717				372	0
GC AMERICA INC.	\$155,171				613				534	0
GE CAPITAL, HEALTHCARE FINANCIAL SERVICES, AN UNINCORPORATED DIVISION OF GENERAL ELECTRIC CAPITAL CO	\$229				4				4	0
GE GLOBAL RESEARCH AN UNINCORPORATED BUSINESS UNIT OF GENERAL ELECTRIC COMPANY		\$24,635				4			0	2
GE HEALTHCARE	\$2,210,703	\$37,838			2,017	3			1,123	59
GEBAUER COMPANY	\$3,962				29				25	1
GEISTLICH PHARMA, NORTH AMERICA, INC.	\$78,603	\$23,478			293	2			243	0
GEMINI MEDICAL LLC	\$12,459				65				39	0
GENENTECH USA, INC.	\$5,662,929				30,013				12,193	29
GENENTECH, INC.	\$123,710,875	\$7,616,623			1,078	906			507	108
GENETICS INSTITUTE LLC	\$300				1				0	1
GENZYME CORPORATION	\$2,874,812	\$5,087			6,684	23			2,642	23
GEORGIA CRYOTHERAPY LP	\$67,206		\$231,396	\$200,625	195		39	39	39	0
GILEAD SCIENCES INC	\$3,579,411				21,392				7,205	30
GIVEN IMAGING LTD.	\$52,288				27				11	0
GIVEN IMAGING, INC.	\$45,165				403				344	0
GLAUKOS CORPORATION	\$212,888	\$1,492	\$57,910	\$1,890,000	421	2	5	5	297	5

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
GLAXOSMITHKLINE, LLC.	\$3,160,237	\$15,848,528			11,747	1,544			2,546	18
GLOBUS MEDICAL, INC.	\$4,083,332	\$39,925			3,006	13			1,063	1
GOETZE-NIEMER CO	\$3,254				16				16	0
GOODE SURGICAL INC	\$2,927				30				10	0
GOTHAM SURGICAL SOLUTIONS & DEVICES, INC.	\$2,715				25				20	0
GREAT LAKES MEDICAL SERVICES, LLC	\$142,022		\$134,235	\$149,969	1,368		191	191	192	0
GREATBATCH, INC.	\$16,294				14				5	0
GREER LABORATORIES, INC.	\$15,271				13				11	1
GRIFOLS THERAPEUTICS INC.	\$9,245	\$15,440			19	4			4	1
GRIFOLS USA, LLC	\$440,318				5,676				3,425	1
GRIFOLS, INC.	\$146,278				106				76	2
GRIFOLS, S.A.	\$19,900				18				6	0
GRUNENTHAL USA INC	\$8,343				17				6	0
GUERBET LLC	\$298,616				186				90	3
GULF STATES CRYOTHERAPY LP	\$4,502		\$152,856	\$32,525	5		5	5	5	0
GYRUS ACMI, INC.	\$79,800				33				7	1
GYRUS ACMI, L.P.	\$8,528				1				0	1
GYRUS ENT, L.L.C.	\$41,145				43				15	2
GYRUS MEDICAL GMBH	\$6,230				1				0	1
GYRUS MEDICAL, INC.	\$10,755				14				8	0
H. LUNDBECK A S	\$122,573	\$5,790			58	7			20	0
HAEMONETICS CORPORATION	\$104,464	\$17,600			195	4			137	11
HALOZYME INC	\$76,816				137				90	0
HALT MEDICAL, INC	\$231,918	\$124,371	\$250,500	\$251,536	233	11	7	7	47	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
HAND BIOMECHANICS LABORATORY	\$65,296				2				2	0
HANSEN MEDICAL, INC.	\$22,639	\$525			144	1			83	0
HARVEST TECHNOLOGIES CORP.	\$31,517	\$37,601			110	9			83	0
HEARTWARE, INC.	\$414,369	\$583,083			962	26			208	74
HEIDELBERG ENGINEERING, INC.	\$197,382				205				146	16
HELENA LABORATORIES CORPORATION	\$3,709				16				6	0
HELIX MEDICAL, LLC	\$60,894				8				7	1
HENRY SCHEIN FINANCIAL SERVICES, LLC	\$71				2				2	0
HENRY SCHEIN PRACTICE SOLUTIONS INC.	\$1,220				19				15	0
HENRY SCHEIN PUERTO RICO, INC.	\$1,567				88				88	0
HENRY SCHEIN, INC.	\$702,736				6,206				3,395	3
HERAEUS KULZER, LLC	\$60,896				484				397	0
HET SYSTEMS LLC	\$538	\$23,424	\$0	\$23,406,794	28	5	2	2	30	1
HF ACQUISITION CO. LLC	\$1,663				28				22	0
HIGHLINE SURGICAL SOLUTIONS, LLC			\$9,600	\$31,098			1	1	1	0
HILL-ROM COMPANY, INC	\$80,927				83				4	27
HILL-ROM HOLDINGS, INC	\$65				1				1	0
HILL-ROM SERVICES PTE, LTD	\$9,800				1				0	1
HILL-ROM SERVICES, INC	\$11,672				7				3	3
HITACHI ALOKA MEDICAL, LTD.	\$41,366				42				18	0
HITACHI MEDICAL SYSTEMS AMERICA, INC.	\$6,529				76				50	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
HI-TECH PHARMACAL CO., INC.	\$155,714				10				2	1
HOFFMANN-LA ROCHE INC.		\$500				1			0	1
HOFFMANN-LA ROCHE LIMITED	\$42,041				27				17	1
HOLLISTER INCORPORATED	\$55,680	\$6,535			256	1			189	24
HORIZON PHARMA USA, INC.	\$323,081	\$6,780			33,243	1			11,844	0
HOSPIRA WORLDWIDE, INC.	\$237,360	\$68,959			1,687	3			1,154	15
HOYA SURGICAL OPTICS, INC	\$17,489				94				56	0
HU-FRIEDY MFG. CO., LLC	\$49,920				322				211	22
HYDROGEL VISION CORPORATION	\$2,422				51				43	0
HYPERION THERAPEUTICS INC.	\$38,817	\$121,950			64	13			60	10
ICAD, INC	\$106,645		\$610,860	\$610,860	198		5	5	106	0
IDEV TECHNOLOGIES, INC.	\$2,534,945	\$5,750	\$7	\$0	10	1	7	7	5	2
ILLINOIS CRYOTHERAPY LP	\$78,326		\$264,640	\$239,686	70		14	14	14	0
IMCLONE SYSTEMS, LLC	\$31,880	\$1,827,334			2	58			8	28
IMPAX LABORATORIES, INC.	\$90,765				527				389	0
IMPLANT DIRECT INTERNATIONAL LLC	\$108,389				1,009				782	0
IMPULSE MONITORING, INC.	\$11				1				1	0
IMRIS INC.	\$7,365				16				14	1
INCONTROL MEDICAL, LLC	\$40,899		\$275,000	\$225,000	7		4	4	5	0
INCYTE CORPORATION	\$690,340	\$10,834,902			2,426	67			1,220	39
INLAND SURGICAL PRODUCTS, LLC	\$174,800		\$450,839	\$450,839	2		2	2	2	0
INNOCUTIS HOLDINGS LLC	\$52,975				661				440	0
INNOVASIS INC	\$182,974				58				24	0
INNOVATIVE CRYOSURGERY, LLC	\$213,321		\$996,790	\$996,790	809		184	184	203	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
INNOVATIVE LASERS, LLC	\$102,045		\$85,366	\$85,366	970		183	183	182	0
INNOVATIVE MEDICAL PRODUCTS, INC.	\$79,660	\$15,288			6	5			7	0
INNOVATIVE OPHTHALMIC PRODUCTS, INC.	\$15,500				9				9	0
INNOVATIVE TRAUMA CARE, INC.	\$10,198				18				6	0
INOGEN, INC.	\$554				37				29	0
INOVA DIAGNOSTICS, INC.	\$1,724				4				4	0
INOVA LABS INC	\$3,530				140				126	0
INSTITUTE FOR TRANSFUSION MEDICINE	\$104,181	\$25,668			28	4			24	1
INSTRUMENTATION LABORATORY COMPANY	\$17,769	\$168,250			49	5			33	5
INSULET CORPORATION	\$196,554				1,438				1,003	12
INSYS THERAPEUTICS INC	\$2,358,104				5,846				1,615	0
INTEGRA LIFESCIENCES SALES LLC	\$12,846				250				169	0
INTEGRA BURLINGTON MA, INC	\$89				2				2	0
INTEGRA LIFESCIENCES CORPORATION	\$1,139,628	\$39,966			1,987	5			993	16
INTEGRA LIFESCIENCES FRANCE LLC	\$989				5				1	0
INTEGRA SALES, INC.	\$37				2				2	0
INTEGRA YORK PA, INC.	\$1,624				13				6	0
INTELLIGENT MEDICAL DEVICES, INC.			\$50,005	\$174,599			3	3	3	0
INTERCELL USA, INC.	\$2,416				6				6	0
INTERRAD MEDICAL, INC.	\$35				1				1	0
INTERSECT ENT, INC.	\$153,364				927				373	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
INTERVENTIONAL SPINE, INC.	\$14,789	\$23,000	\$2,279,760	\$2,279,760	7	1	17	17	23	0
INTUITIVE SURGICAL OPERATIONS, INC.	\$516,386	\$309,000			172	3			24	10
INTUITIVE SURGICAL, INC.	\$7,967,438				16,846				3,638	98
INVACARE CORPORATION	\$490				4				3	0
IPSEN BIOPHARM LIMITED	\$1,234				8				1	0
IPSEN BIOPHARMACEUTICALS, INC	\$189,994	\$156,344			1,189	54			694	16
IPSEN BIOSCIENCE INC		\$13,471				2			0	2
IPSEN INNOVATION	\$42,371				39				16	0
IPSEN PHARMA SAS	\$40,712	\$11,750			4	1			0	1
IRHYTHM TECHNOLOGIES, INC.	\$68,489	\$86,900	\$325,802	\$152,286	15	1	4	4	13	1
IROKO PHARMACEUTICALS, LLC	\$310,188				682				89	0
IRONWOOD PHARMACEUTICALS, INC	\$166,611				5,728				3,944	1
ISCI HOLDINGS INC.	\$2,088				2				2	0
ISCREEN VISION INC.	\$99				8				8	0
ISORAY, INC	\$95,053	\$7,000			79	1			65	0
ISOTIS ORTHOBIOLOGICS, INC.	\$4,233				67				44	0
ISTO TECHNOLOGIES, INC.	\$81,807	\$10,500	\$1,279,470	\$2,404,261	63	1	19	19	69	2
ITXM CLINICAL SERVICES	\$52,167				30				2	6
ITXM DIAGNOSTICS	\$1,360				4				0	1
J. MORITA USA, INC.	\$32,372				32				9	5
JAN MEDICAL INC.	\$4,260				12				7	0
JANSSEN BIOTECH, INC.	\$1,077,053				27,092				11,174	17
JANSSEN DIAGNOSTICS, LLC	\$58,009	\$12,848			24	2			11	3
JANSSEN GLOBAL SERVICES, LLC	\$107,435				91				37	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
JANSSEN PHARMACEUTICALS, INC	\$9,742,710				105,318				45,025	57
JANSSEN PRODUCTS, LP	\$986,255				3,468				2,552	2
JANSSEN RESEARCH & DEVELOPMENT, LLC	\$430,726	\$4,608,571			259	256			167	98
JANSSEN SCIENTIFIC AFFAIRS, LLC	\$2,715,121				3,890				1,874	11
JANSSEN SUPPLY GROUP, LLC	\$52				3				3	0
JAZZ PHARMACEUTICALS INC.	\$418,399	\$856,819			2,407	19			1,515	14
JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC.	\$29,958				393				336	2
JOHNSON & JOHNSON MEDICAL DEVICES & DIAGNOSTICS GROUP - LATIN AMERICA, L.L.C.	\$20,184				12				5	0
JOHNSON & JOHNSON VISION CARE, INC.	\$856,553	\$445,193			5,475	57			3,068	1
JOHNSON AND JOHNSON INTERNATIONAL	\$9,870				80				18	0
JOIMAX, INC.	\$34,800				3				3	0
JUSTRIGHT SURGICAL LLC	\$1,073		\$612,266	\$612,266	6		4	4	5	0
K2M, INC.	\$631,497	\$800			647	1			244	1
KADMON CORPORATION LLC	\$33,109	\$13,206			26	3			6	1
KADMON PHARMACEUTICALS LLC	\$80,706				1,005				700	1
KAIROS SURGICAL INC	\$17,719				70				56	0
KANSAS CRYOSURGERY ASSOCIATES LLC	\$40,375		\$134,807	\$177,222	56		14	14	14	0
KARL STORZ ENDOSCOPIA MEXICO, S.A.	\$1,097				3				1	0
KARL STORZ ENDOVISION, INC.	\$92,027				2				1	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
KARL STORZ IMAGING, INC.	\$1,986				2				0	2
KARL STORZ LITHOTRIpsy-AMERICA, INC.	\$893				10				7	0
KARLSTORZ ENDOSCOPY-AMERICA	\$4,298,247	\$29,790			9,226	3			457	376
KATENA PRODUCTS, INC.	\$5,000				2				2	0
KAVO TECHNOLOGIES LLC	\$203				6				6	0
KCI USA, INC	\$457,414				1,953				1,493	1
KEDRION BIOPHARMA, INC.	\$60,022				162				68	0
KENSEY NASH	\$10,779				15				10	0
KERR CORPORATION	\$255,620				939				671	0
KEYSTONE DENTAL INC.	\$177,249	\$4,400	\$319,059	\$402,014	119	2	1	1	121	0
KEYSTONE SURGICAL SYSTEMS, INC.	\$713				1				0	1
KINAMED, INC.	\$1,790				2				2	0
KLS MARTIN L.P.	\$656,788				305				127	46
KONICA MINOLTA MEDICAL IMAGING USA, INC.	\$1,234				1				1	0
KOVEN TECHNOLOGY, INC.	\$1,000				1				1	0
KOWA COMPANY, LTD.	\$41,119				8				2	0
KOWA PHARMACEUTICAL CO.LTD	\$145,445				8,509				6,314	0
KOWA RESEARCH INSTITUTE, INC.	\$15,840				14				6	0
KURARAY AMERICA INC.	\$12,960				37				35	0
K-V PHARMACEUTICAL COMPANY	\$509	\$12,155			1	6			1	2
LAERDAL MEDICAL CORPORATION	\$34,999				7				7	0
LAKE REGION MANUFACTURING, INC. D.B.A. LAKE REGION	\$11,224				21				15	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
MEDICAL										
LANNETT COMPANY INC	\$2,500				1				1	0
LANTHEUS MEDICAL IMAGING, INC.	\$175,905				1,368				723	1
LANX, INC.	\$5,069,250	\$2,000	\$4,421,827	\$6,905,278	513	1	43	43	202	2
LASER SPECIALTY MEDICAL, LLC	\$150,543		\$162,703	\$275,615	1,164		197	197	195	0
LDR HOLDING CORPORATION			\$10,000	\$418,490			2	2	2	0
LDR MEDICAL	\$33,674				4				2	0
LDR SPINE USA, INC	\$754,306	\$2,160			2,695	1			698	5
LED DENTAL INC.	\$290		\$2,500	\$43,875	3		1	1	4	0
LEICA MICROSYSTEMS INC.	\$29,205				8				4	0
LEMAITRE VASCULAR, INC.	\$60,648	\$5,502			440	3			237	3
LENSAR, INC.	\$58,771		\$3,878,630	\$4,335,721	90		16	16	62	0
LEO PHARMA AS	\$48,981	\$72,960			84	4			21	1
LEO PHARMA INC.	\$453,147	\$11,225			3,898	7			1,890	2
LIBERTY SURGICAL, INC	\$4,693				53				33	0
LIFE TECHNOLOGIES CORPORATION	\$565				7				7	0
LIFECCELL CORPORATION	\$2,264,080	\$177,830			5,933	6			2,118	25
LIFENET HEALTH INC.	\$29,012				22				10	0
LIFESCAN, INC.	\$95,783				4,150				2,101	2
LIFEWATCH SERVICES INC	\$154,153				233				195	12
LILLY USA, LLC	\$4,564,016	\$583,257			65,519	74			24,218	113
LINDE GAS NORTH AMERICA, LLC	\$13,631	\$25,000			10	1			0	10
LINEAGE THERAPEUTICS INC.	\$3,445				28				24	0
LINVATEC CORPORATION	\$943,128				944				201	18

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
LIPOSCIENCE, INC.	\$189,056		\$215,496	\$60,670	703		7	7	256	0
LIVENTA BIOSCIENCES INC.	\$21,607				1				1	0
LOMBARD MEDICAL TECHNOLOGIES INC.	\$34,436	\$21,100			350	7			203	7
LSI SOLUTIONS INC	\$109,704				47				46	1
LUITPOLD PHARMACEUTICALS INC	\$75,379	\$50,157			4,989	32			3,146	5
LUMENIS, INC	\$58,919				23				21	0
LUMINEX CORPORATION	\$23,211				14				1	12
LUMINEX MOLECULAR DIAGNOSTICS	\$42,499				5				2	3
LUNDBECK LLC	\$827,011	\$198,612			5,633	38			2,526	8
LUNG BIOTECHNOLOGY CORP	\$145,706				2,962				1,130	1
LUPIN PHARMACEUTICALS, INC	\$89,233				2,324				1,433	0
LUTONIX, INC.	\$148,584	\$101,358			40	25			11	11
LVB ACQUISITION, INC.			\$1,375,000	\$1,120,625			9	9	9	0
M2S, INC	\$105,551				18				15	0
MACULOGIX, INC.	\$10,077				5				2	0
MAILLEFER INSTRUMENTS HOLDING SARL	\$80,114				17				4	0
MAKO SURGICAL CORP.	\$6,385,276				1,118				379	1
MALLINCKRODT LLC	\$897,739	\$99,475			9,969	3			4,198	3
MAQUET CARDIOPULMONARY AG	\$117,771	\$7,894			8	1			1	2
MAQUET CARDIOVASCULAR L.L.C.	\$843	\$600			4	2			5	1
MAQUET CARDIOVASCULAR U.S. SALES, L.L.C.	\$133,557				767				565	17

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
MAR COR PURIFICATION, INC.	\$13				1				1	0
MARATHON PHARMACEUTICALS, LLC	\$30,830				5				2	0
MARINE POLYMER TECHNOLOGIES, INC.	\$16,000				1				1	0
MASIMO CORPORATION	\$954,623				510				237	29
MATERIALISE DENTAL INC	\$7,727				23				19	0
MATERIALISE DENTAL NV BELGIUM	\$5,653				3				3	0
MATERIALISE NV	\$18,750				1				1	0
MATERIALISE USA LLC	\$1,051				4				2	0
MAUNA KEA TECHNOLOGIES, INC.	\$40,093				107				69	2
MCKESSON MEDICAL-SURGICAL, INC.	\$179				15				5	0
MCKESSON SPECIALTY CARE DISTRIBUTION CORP.	\$207,561				1,375				463	0
MCKESSON TECHNOLOGIES, INC.	\$9,957				32				24	5
MEDA PHARMACEUTICALS, INC.	\$341,753	\$70,330			4,775	11			3,431	0
MEDACTA USA	\$3,358				14				10	0
MEDAFOR, INC.	\$45,000				10				2	0
MEDARTIS INC.	\$133,660				88				75	0
MED-EL CORPORATION	\$65,672				172				125	0
MEDELA INC.	\$57,534				18				7	10
MEDERI THERAPEUTICS INC	\$41,042				12				11	0
MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC.	\$225,566				162				22	1
MEDICAL GRAPHICS CORPORATION	\$99				4				3	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
MEDICAL INVESTMENT ADVISORS LLC	\$8,700				5				3	0
MEDICAL MODELING INC.	\$14,427				60				59	1
MEDICOMP INC	\$8,420				180				119	0
MEDICREA USA, CORP.	\$42,293	\$2,000			148	1			64	1
MEDIGUS LTD.	\$21,085				3				2	0
MEDIMMUNE, LLC	\$648,794	\$1,164,190			3,557	32			2,288	27
MEDINC OF TEXAS	\$14,944				105				81	0
MEDISTIM USA, INC.	\$1,859				22				21	0
MEDISYSTEMS CORPORATION	\$70				1				1	0
MEDIVANCE, INC.	\$1,080				19				19	0
MEDIVATION INC.	\$289,177	\$106,522			2,687	34			1,565	17
MEDIVATORS INC.	\$18,996				74				46	16
MEDLINE INDUSTRIES, INC.	\$264,819		\$6,148,195	\$15,123,198	361		6	6	216	71
MEDRAD INC.	\$43,918				46				12	4
MEDSHAPE, INC.	\$18,346				17				12	0
MEDTEC, INC.	\$372				4				4	0
MEDTRONIC MINIMED, INC.	\$357,066	\$4,832			3,981	4			1,553	10
MEDTRONIC SOFAMOR DANEK USA, INC.	\$6,208,331	\$81,006			6,362	17			2,188	19
MEDTRONIC USA, INC.	\$1,473,466	\$209,673			14,958	28			5,338	35
MEDTRONIC VASCULAR, INC.	\$4,667,176	\$443,732			23,722	145			6,149	62
MEDTRONIC XOMED, INC.	\$573,723	\$29,687			1,992	1			1,140	8
MEDTRONIC, INC.	\$24,410	\$10,552			326	8			129	4
MEDWEST ASSOCIATES	\$11,454				29				27	0
MEGADYNE MEDICAL PRODUCTS	\$9,855				9				7	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
INC										
MEISINGER USA, LLC	\$32,272				19				17	0
MEMPHIS CRYO ASSOCIATES LP	\$32,215		\$99,823	\$76,176	45		9	9	9	0
MENICON AMERICA, INC.	\$4,900				6				6	0
MENTOR WORLDWIDE LLC	\$1,040,631	\$185,871			2,314	40			1,083	6
MERCATOR MEDSYSTEMS, INC.	\$224				5				5	0
MERCEDES MEDICAL, LLC	\$2,060				161				61	0
MERCK SHARP & DOHME CORPORATION	\$7,868,995	\$10,126,897			55,278	2,286			30,735	68
MERCURY ENTERPRISES, INC.	\$97				3				3	0
MERIDIAN BIOSCIENCE INC.	\$12,159	\$3,075			124	1			45	22
MERIDIAN MEDICAL TECHNOLOGIES, INC.		\$3,793				1			0	1
MERIT MEDICAL SYSTEMS INC	\$185,788	\$103,981	\$760,321	\$676,753	307	13	2	2	185	13
MERZ NORTH AMERICA, INC.	\$861,201				5,215				2,545	1
MERZ PHARMACEUTICALS GMBH	\$175,338	\$19,935			58	1			24	1
MERZ PHARMACEUTICALS, LLC		\$212,447				20			7	2
MERZ, INC.	\$1,714				19				18	0
MESA SURGICAL, LLC	\$554,876		\$465,311	\$465,311	5		6	6	6	0
METREX RESEARCH, LLC	\$5,678				70				41	0
METRIC MEDICAL DEVICES, INC.	\$136		\$25,000	\$25,000	5		1	1	6	0
MICHIGAN MOBILE UROLOGY SERVICES LLC	\$82,047		\$222,096	\$376,184	250		51	51	51	0
MICROAIRE SURGICAL INSTRUMENTS LLC	\$95,950				88				20	6
MICROGENICS CORPORATION	\$905				1				0	1
MICROLINESURGICAL INC	\$24,760				22				16	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
MICROMED INC	\$5,177				21				19	0
MICROVENTION, INC.	\$146,045	\$95,031			282	61			103	4
MICRUS ENDOVASCULAR LLC		\$9,125				1			0	1
MID-ATLANTIC SURGICAL SYSTEMS, LLC	\$24,825				121				72	0
MIDMARK CORPORATION	\$55,711				52				52	0
MIDSOUTH ORTHOPEDICS	\$3,638				14				10	0
MIDWEST CRYOTHERAPY LP	\$45,771		\$182,277	\$266,782	75		15	15	15	0
MIDWEST SURGICAL ALLIANCE, LLC	\$26,500		\$277,493	\$277,493	1		6	6	4	0
MILLENNIUM PHARMACEUTICALS, INC.	\$2,953,741	\$5,909,088			4,471	1,282			1,873	92
MILLIKEN HEALTHCARE PRODUCTS, LLC	\$7,414				15				13	0
MINDRAY DS USA, INC.	\$22,346				90				35	6
MIS IMPLANTS TECHNOLOGIES, INC.	\$33,221	\$1,500			62	1			61	0
MISSION PHARMACAL COMPANY	\$117,081	\$7,300			170	1			55	1
mitsubishi electric corporation	\$153				1				1	0
MLH-RX, LLC	\$4,500				5				3	0
MOBILE CRYOSURGICAL PARTNERS LP	\$24,312		\$248,106	\$186,392	26		13	13	13	0
MODERN ORTHOPEDIC CONSULTANTS	\$1,983				14				13	0
MOLNLYCKE HEALTH CARE AB	\$12,011				6				4	0
MOLNLYCKE HEALTH CARE US, LLC	\$40,587				180				123	17
MONAGHAN MEDICAL CORPORATION	\$10,157				12				4	8

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
MONTERIS MEDICAL CORPORATION	\$32,044				59				35	0
MRI INTERVENTIONS, INC.	\$101,301	\$5,079	\$1,414,478	\$1,002,726	48	1	57	57	63	8
MUSCULOSKELETAL TRANSPLANT FOUNDATION INC.	\$380,515	\$439,096			687	26			328	14
MYDENT INTERNATIONAL, INC.	\$1,333				23				23	0
MYLAN INSTITUTIONAL INC.	\$4,787				8				5	1
MYLAN PHARMACEUTICALS INC.	\$15,799				3				2	1
MYLAN SPECIALTY L.P.	\$935,291				12,184				8,017	3
NANOSPHERE, INC.	\$1,642				4				4	0
NATIONAL DENTEX CORPORATION	\$15,275				429				407	0
NAUTILUS NEUROSCIENCES, INC.	\$19,656				362				137	0
NAVIDEA BIOPHARMACEUTICALS, INC.	\$1,790				33				30	0
NCONTACT SURGICAL, INC	\$108,102		\$0	\$17,600	306		1	1	104	0
NDI MEDICAL, LLC	\$8,595		\$737,293	\$859,127	72		6	6	62	0
NEIGHBORHOOD DIABETES, INC.	\$10				1				1	0
NEOMEND, INC.	\$134,166	\$135,384			287	22			149	9
NESTLE HEALTHCARE NUTRITION INC.	\$3,500				2				2	0
NEURO KINETICS, INC.	\$19,980		\$52,377	\$53,775	1		2	2	1	0
NEUROLOGICA CORPORATION, A SUBSIDIARY OF SAMSUNG ELECTRONICS	\$2,257				24				5	3
NEUROMETRIX INC	\$24,814				9				4	0
NEURONETICS, INC.	\$57,620	\$17,098			565	7			304	2
NEUROPACE, INC.	\$16,471	\$572,486	\$688,509	\$2,368,548	89	74	6	6	44	21

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
NEUWAVE MEDICAL, INC.	\$275,931		\$2,672,745	\$2,166,959	80		7	7	39	19
NEW ENGLAND CRYOTHERAPY LP	\$12,271		\$109,432	\$59,715	35		7	7	7	0
NEW WAVE SURGICAL CORP.	\$722		\$77,000	\$3,310,350	4		14	14	14	0
NEW WORLD MEDICAL, INC.	\$9,539				2				2	0
NEW YORK BLOOD CENTER, INC.	\$66,119				29				13	3
NEXTREMITY SOLUTIONS INC.	\$21,831				89				51	0
NIDEK INCORPORATED	\$20,615				2				0	2
NIHON COCHLEAR CO LTD	\$5,518				2				1	0
NIHON KOHDEN AMERICA, INC.	\$5,867	\$68,715			20	1			1	17
NINEPOINT MEDICAL, INC.	\$361,028				106				69	1
NIPPON BOEHRINGER INGELHEIM CO., LTD.	\$156,804				27				4	0
NOBEL BIOCARE USA	\$1,048,573				4,852				2,277	1
NONIN MEDICAL, INC.	\$366	\$556			12	1			9	0
NORGENIX PHARMACEUTICALS, LLC	\$1,510				75				75	0
NORMATEC INDUSTRIES, LP	\$133				2				2	0
NORTH ALABAMA SURGICAL SERVICES GP, LLC			\$30,000	\$30,000			3	3	3	0
NORTH ALABAMA SURGICAL SERVICES, LLC			\$120,000	\$120,000			3	3	3	0
NORTH IDAHO SURGICAL COOPERATIVE, LLC			\$24,563	\$24,563			5	5	3	0
NORTH TEXAS SURGICAL SERVICES, LLC	\$366		\$384,000	\$384,000	4		12	12	12	0
NORTHEAST CRYOTHERAPY LP	\$31,429		\$198,424	\$115,201	164		36	36	34	0
NOVABAY_PHARMACEUTICALS,_I NC.	\$83,526	\$19,755	\$62,700	\$62,700	4	1	5	5	8	1

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
NOVADAQ TECHNOLOGIES INC.	\$209,279	\$36,750			392	3			392	3
NOVARTIS CONSUMER HEALTH INC.	\$162,733				77				21	0
NOVARTIS PHARMA AG	\$246,403	\$1,110,171			163	16			65	3
NOVARTIS PHARMACEUTICALS CORPORATION	\$6,751,358	\$1,814,796			39,534	313			15,938	49
NOVARTIS VACCINES AND DIAGNOSTICS INC	\$580,158	\$126,589			4,701	1			3,380	2
NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.	\$7,970				6				2	0
NOVEN PHARMACEUTICALS, INC.	\$8,857				29				16	0
NOVEN THERAPEUTICS, LLC	\$354,112				6,707				4,719	1
NOVO NORDISK AS	\$795,576	\$326,802			605	54			131	18
NOVO NORDISK HEALTH CARE AG	\$44,730				18				4	0
NOVO NORDISK INC	\$4,503,473	\$162,738			63,214	15			17,756	58
NOVOCURE INC.	\$324,074	\$48,449	\$16,187,445	\$16,187,445	615	8	14	14	174	3
NOVOCURE ISRAEL LTD		\$750				2			0	1
NOVOCURE LIMITED			\$16,187,445	\$16,187,445			14	14	14	0
NOVOSOURCE, INC.	\$404		\$2,154,020	\$1,821,882	4		50	50	39	0
NOVUS SCIENTIFIC INC.	\$105				1				1	0
NPS PHARMACEUTICALS, INC.	\$108,616	\$150,148			724	95			518	6
NSK AMERICA CORPORATION	\$100				6				6	0
NUCLETRON B.V.	\$7,175				9				7	0
NUTECH SPINE, INC.	\$23,721		\$603,250	\$1,932,000	45		22	22	35	0
NUVASIVE, INC.	\$4,784,376	\$4,200			5,243	2			1,049	0
NXSTAGE MEDICAL, INC.	\$73,687				375				301	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
OCTAPHARMA USA, INC.	\$86,051	\$47,203			218	17			149	2
OCULUS, INC.	\$61,762				24				7	0
OKLAHOMA UROLOGIC THERAPIES LP	\$127,401		\$438,515	\$400,980	56		10	10	11	0
OLEA MEDICAL	\$3,969				1				1	0
OLIVE MEDICAL CORPORATION			\$127,508	\$129,830			4	4	4	0
OLYMPUS AMERICA INC.	\$535,799				1,611				1,028	9
OLYMPUS BIOTECH CORPORATION	\$8,620				132				120	0
OLYMPUS CORPORATION		\$1,600				1			1	0
OLYMPUS CORPORATION OF THE AMERICAS	\$1,188,103				763				231	12
OLYMPUS ENDO TECHNOLOGY AMERICA INC.	\$780				1				1	0
OLYMPUS LATIN AMERICA, INC.	\$2,673				6				2	0
OLYMPUS MEDICAL SYSTEMS CORPORATION	\$3,462	\$485,180			9	9			15	2
OLYMPUS WINTER & IBE GMBH	\$10,984	\$7,080			1	2			3	0
OMNI SURGICAL LLC	\$552,116				55				17	0
OMNIGUIDE, INC.	\$114,470		\$2,250	\$1,350	254		1	1	177	4
OMNILIFE SCIENCE, INC	\$35,059	\$7,434	\$1,467,066	\$20	76	2	20	20	60	0
ONCOLOGY PHYSICIAN RESOURCE, PLLC			\$79,000	\$79,000			79	79	79	0
ONSET DERMATOLOGY, INC	\$77,873				1,592				910	0
ON-X LIFE TECHNOLOGIES, INC	\$123,683	\$184,726			286	23			158	14
ONY, INC.	\$385	\$20,000			5	1			5	1
ONYX PHARMACEUTICALS, INC., AN AMGEN SUBSIDIARY	\$1,499,536	\$442,329			5,099	11			1,998	28

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
OPHTEC USA, INC.		\$3,025				5			5	0
OPTIMEDICA CORPORATION	\$689,066		\$12	\$0	73		12	12	56	0
OPTIMER PHARMACEUTICALS INC	\$284,966	\$263,183			2,058	7			1,399	6
OPTOS PLC	\$157,661				112				55	0
OPTOS, INC.	\$10,260				276				275	0
OPTOVUE, INC.	\$40,062	\$5,945			154	2			132	0
ORIGIO INC.	\$1,370				12				10	0
ORION CORPOTION	\$205				3				3	0
ORMCO CORPORATION	\$175,538				1,024				457	0
ORTHALIGN INC	\$3,040				10				7	0
ORTHO DEVELOPMENT CORPORATION	\$956,510				183				22	0
ORTHO KINEMATICS, INC.	\$1,141		\$150,000	\$150,000	9		1	1	10	0
ORTHO ORGANIZERS, INC.	\$287,107				232				85	0
ORTHO RESTORE, LLC			\$47,536	\$47,536			4	4	3	0
ORTHO-CLINICAL DIAGNOSTICS, INC.	\$58,159	\$42,191			53	1			16	8
ORTHOFIX INTERNATIONAL N.V.	\$320,916	\$907			511	8			317	0
ORTHOPEDIATRICS CORP.	\$219,012		\$11,846,053	\$18,526,337	156		70	70	159	0
ORTHOPRO, LLC	\$21,445				29				13	0
ORTHOSENSOR INC.	\$2,782		\$1,172,126	\$1,783,854	25		11	11	31	0
OSPREY MEDICAL INC		\$5,000				1			0	1
OSSEUS FUSION SYSTEMS, LLC	\$32,670				7				2	0
OSTEOGENICS BIOMEDICAL INC.	\$725				1				0	1
OSTEOMED LLC	\$209,792				1,314				383	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
OTICON MEDICAL, LLC	\$68,092				40				11	15
OTSUKA AMERICA PHARMACEUTICAL, INC.	\$11,004,050	\$1,084,868			64,765	15			22,442	68
OTSUKA PHARMACEUTICAL CO., LTD.	\$1,577,044				220				35	1
OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.	\$71,576	\$1,115,983			56	402			91	36
OWENS & MINOR DISTRIBUTION, INC.	\$219,725				37				4	31
OXFORD IMMUNOTEC INC.	\$47,562				24				9	0
OZARK CRYOSURGERY, LLC	\$181,514		\$100,229	\$233,841	1,002		189	189	200	0
PACIFIC MEDICAL, INC	\$40,168				199				101	0
PACIRA PHARMACEUTICALS INCORPORATED	\$771,360	\$17,626			2,566	7			1,802	5
PANASONIC CORPORATION OF NORTH AMERICA	\$15,000				1				0	1
PANORAMIC RENTAL CORP.	\$20,475				51				51	0
PAR PHARMACEUTICAL, INC.	\$91,128	\$36,226			5,603	5			1,805	2
PARADIGM SPINE, LLC	\$86,045		\$17,498,381	\$31,891,429	206		51	51	156	0
PARAGON 28, INC.	\$5,975				71				66	0
PARI RESPIRATORY EQUIPMENT, INC.	\$79,588				1				1	0
PATTERSON COMPANIES, INC.	\$698,849				2,031				1,386	0
PDP HOLDINGS, LLC	\$1,165		\$950,000	\$950,000	5		8	8	8	0
PEERLESS SURGICAL INC.	\$8,671				49				20	0
PENTAX MEDICAL SHANGHAI CO., LTD	\$16,961				9				4	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
PENTAX OF AMERICA, INC.	\$382,949				103				44	12
PENUMBRA, INC.	\$237,257	\$149,451	\$2,219,791	\$5,721,484	938	19	14	14	355	13
PERNIX THERAPEUTICS HOLDINGS, INC.	\$95,021				214				202	0
PERRIGO COMPANY PLC	\$40,253				9				8	1
PETER BRASSELER HOLDINGS, LLC	\$322,207				259				150	3
PFIZER CORPORATION HONG KONG LIMITED	\$6,853				2				1	0
PFIZER INC.	\$21,207,375	\$18,286,715			112,073	1,771			43,640	243
PFIZER INTERNATIONAL LLC	\$347,892	\$74,936			329	20			79	6
PFIZER LIMITED	\$39,249				4				2	1
PFIZER PHARMACEUTICALS KOREA LIMITED	\$16,328				2				2	0
PFIZER PHARMACEUTICALS LLC	\$5,497				65				52	1
PHADIA AB	\$2,452				5				4	0
PHADIA US INC.	\$256,204	\$20,000			5,112	1			4,009	2
PHARMACIA & UPJOHN COMPANY LLC	\$1,000	\$9,041			1	13			0	4
PHARMEDIUM SERVICES LLC	\$30,109				1				1	0
PHILIPS ELECTRONICS NORTH AMERICA CORPORATION	\$669,807	\$688,187			2,944	32			2,387	21
PHOTOCURE INC	\$33,403				100				69	0
PHYSICIAN DISCOVERIES, LLC			\$659,655	\$601,905			88	88	88	0
PIERRE FABRE PHARMACEUTICALS, INC.	\$2,927				9				4	0
PINNACLE BIOLOGICS, INC	\$101,859				120				33	6
PINNACLE, INC	\$3,422				98				61	0
PIVOT MEDICAL, INC.	\$26,331		\$53,550	\$174,710	45		11	11	34	2

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
PLANMECA USA, INC.	\$26,862				91				78	0
PLANMED, INC.	\$249				2				2	0
PLASMA SURGICAL, INC.	\$18,116				53				46	0
PLEXXIKON INC.		\$452,941				39			9	14
PRECISION SPINE, INC.	\$234,275				34				16	0
PRECISION THERAPEUTICS, INC.	\$22,373	\$11,300			225	2			218	5
PREMIER DENTAL PRODUCTS COMPANY	\$24,978				157				103	0
PROCEDURAL ORTHOPEDICS INC	\$3,339				24				8	0
PRODIGY SURGICAL DISTRIBUTION, INC.	\$25,871				63				38	1
PROFESSIONAL HOSPITAL SUPPLY, INC.	\$14,700				4				0	3
PROMETHEUS LABORATORIES INC.	\$233,177				2,490				1,317	0
PROMIUS PHARMA LLC	\$250,043				1,342				794	0
PRONOVA CORPORATION	\$639				36				36	0
PROSTRAKAN, INC.	\$15,892				577				466	0
PROVISTA DIAGNOSTICS, INC.	\$4,096				110				61	0
PSS WORLD MEDICAL INC.	\$8,721				41				41	0
PULMONX CORPORATION			\$1,563,403	\$163,816			16	16	15	0
PULPDENT CORPORATION	\$19,654				7				7	0
PURDUE PHARMA L.P.	\$2,232,441	\$2,275			16,613	1			10,803	5
PURDUE PRODUCTS L.P.	\$5,670				4				1	0
PURDUE TRANSDERMAL TECHNOLOGIES L.P.	\$821,210				1,742				905	3
PURELIFE, LLC	\$186,687				3,261				1,504	0
PYLANT MEDICAL	\$3,910				36				32	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
QIAGEN SCIENCES, LLC	\$232,456				414				307	34
QOL MEDICAL, LLC	\$45,442	\$27,358			109	3			65	1
QUEST MEDICAL INC.	\$16,261				32				26	0
QUEST MEDICAL LLC	\$2,489				14				8	0
QUESTCOR PHARMACEUTICALS	\$2,825,569				16,319				5,342	2
QUIDEL CORPORATION	\$42,975				50				18	0
R&M DISTRIBUTING, LLC	\$3,416				13				9	0
RADIOMETER AMERICA, INC	\$10,100				2				2	0
RADIOMETER AMERICA, INC.	\$5,113	\$50,313			15	4			15	4
RAINTREE ESSIX INC	\$81,965				249				209	0
RAMSAY MEDICAL, INC	\$1,331				17				10	0
RANBAXY INC.	\$348,629	\$24,638			2,399	2			1,168	0
RAPID PATHOGEN SCREENING, INC.	\$232	\$52,300	\$6,058,931	\$31,113,021	9	3	58	58	68	0
RAPTOR PHARMACEUTICALS	\$53,773				42				22	0
RARE DISEASE THERAPEUTICS, INC.	\$108				4				4	0
RAYSEARCH LABORATORIES AB		\$72,050				1			0	1
REBISCAN	\$1,000				3				2	1
RECKITT BENCKISER PHARMACEUTICALS INC.	\$337,504	\$1,121			4,239	2			2,486	3
REDMEDICAL, LLC	\$996				34				33	0
REGENERON PHARMACEUTICALS, INC.	\$866,331	\$582,256			2,813	145			1,054	23
REICHERT, INC.	\$7,414				7				6	0
RELIANCE MEDICAL PRODUCTS, INC.	\$59				1				1	0
REMEL, INC.	\$7,561				1				0	1

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
RENAISSANCE PHARMA, INC.	\$33,633				304				243	0
RENOVIS SURGICAL TECHNOLOGIES, INC.	\$1,399		\$15,848,941	\$21,187,635	3		21	21	14	0
RESMED CORP	\$26,644	\$85,851			459	18			398	6
RESPIRATORY TECHNOLOGIES, INC.	\$16,863				566				503	1
REVERSE MEDICAL CORPORATION	\$9,800				3				2	0
REVISION OPTICS, INC.	\$83,886				35				17	0
RICHARD-ALLAN SCIENTIFIC COMPANY	\$20,053				14				4	5
RIKCO INTERNATIONAL, LLC	\$26,568				217				84	0
RMO, INC.	\$385				14				9	0
ROANOKE AREA SURGICAL LASERS, LLC	\$90,000		\$85,283	\$174,236	1,370		192	192	190	0
ROCHE DIAGNOSTICS CORPORATION	\$270,830	\$38,613			2,151	1			1,614	15
ROCHE DIAGNOSTICS GMBH	\$25,584				5				4	1
ROCHE DIAGNOSTICS INTERNATIONAL LTD	\$35,793				20				9	0
ROCHE DIAGNOSTICS OPERATIONS, INC.	\$8,400	\$475,114			22	14			3	9
ROCHE HEALTH SOLUTIONS INC.	\$28,600				7				3	0
ROCHE MOLECULAR SYSTEMS, INC.	\$58,111	\$21,200			37	2			14	2
ROCHE PRODUCTS LIMITED	\$24,012				49				16	0
ROCHE TCRC, INC.	\$188,879	\$978,013			60	28			21	8
ROCHESTER MEDICAL CORPORATION	\$1,047				44				41	0
ROCKY MOUNTAIN	\$6,000		\$123,655	\$29,669	16		4	4	4	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
CRYOTHERAPY LP										
ROHO, INC.	\$631				5				1	4
ROMARK LABORATORIES, LC	\$23,813				1,013				655	0
ROXANE LABORATORIES, INC.	\$2,348,187				48				9	1
RSB SPINE, LLC			\$596,934	\$368,131			4	4	4	0
RT ONCOLOGY SERVICES CORPORATION	\$7,444		\$7,709,408	\$10,305,160	16		265	265	251	0
RTI SURGICAL, INC.	\$319,268	\$13,114			383	3			260	0
S. ALABAMA SURGICAL SERVICES GP, LLC			\$20,000	\$20,000			4	4	4	0
S. ALABAMA SURGICAL SERVICES, LLC	\$856		\$140,000	\$140,000	4		4	4	4	0
SAFCO DENTAL SUPPLY CO.	\$3,092				12				11	0
SAFE ORTHOPAEDICS, LLC	\$340				3				3	0
SAFERAY SPINE, LLC	\$88				1				1	0
SAFEWIRE, LLC	\$158				3				2	0
SALIX PHARMACEUTICALS, LTD	\$1,825,486	\$7,238			13,945	1			6,703	29
SAMSUNG ELECTRONICS AMERICA, INC.	\$594				5				5	0
SAN FRANCISCO SURGICAL SERVICES, LLC	\$808		\$60,000	\$60,000	6		2	2	2	0
SANDHILL SCIENTIFIC	\$1,250				1				1	0
SANDOZ INC.	\$156,738				1,984				1,290	5
SANOVI PASTEUR INC.	\$218,824	\$353,740			4,513	143			3,797	16
SANOVI US SERVICES INC.	\$630,806	\$2,874,975			208	336			85	82
SANOVI-AVENTIS U.S. LLC	\$2,880,363	\$752,374			22,473	97			13,564	97
SANTARUS, INC	\$4,237,487	\$45,308			9,623	3			5,051	11
SCS BOEHRINGER INGELHEIM	\$703				2				2	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
COMM.V										
SEAPEARL INC	\$3,526				30				25	0
SEASPINE, INC.	\$569,105				71				20	0
SEATTLE GENETICS, INC.	\$749,387	\$2,840,275			2,033	67			961	12
SEFL CRYO ASSOCIATES LLC	\$6,661		\$61,543	\$41,942	15		5	5	5	0
SEIKAGAKU CORPORATION		\$2,047				13			13	0
SEKISUI DIAGNOSTICS LLC	\$1,532	\$2,400			2	1			3	0
SENATE SURGICAL DISTRIBUTION, LLC			\$41,117	\$41,117			7	7	6	0
SENECA MEDICAL, INC.	\$583				2				1	1
SENSUS HEALTHCARE LLC	\$35,684		\$1,100,000	\$1,100,000	58		4	4	56	1
SEPTODONT INC.	\$62,899				332				118	0
SEQUOIA SURGICAL DISTRIBUTORS, LLC			\$55,831	\$55,831			4	4	3	0
SEYER PHARMATEC, INC.	\$19				1				1	0
SHIONOGI INC	\$1,873,548				16,048				8,779	0
SHIRE US HOLDINGS	\$1,547,422	\$316,026			26,053	47			13,822	25
SI-BONE, INC.	\$389,036		\$5,777,662	\$17,742,994	1,989		55	55	725	2
SIEMENS HEARING INSTRUMENTS, INC.	\$2,560	\$33,957			46	1			30	1
SIEMENS MEDICAL SOLUTIONS USA, INC.	\$2,418,441	\$6,471			2,481	4			787	66
SIENTRA, INC.	\$157,994	\$60,175	\$0	\$0	920	149	1	1	912	0
SIESTA MEDICAL, INC.	\$2,200		\$1	\$2,600	1		1	1	2	0
SIGMA-TAU PHARMACEUTICALS, INC.	\$120,061				168				101	3
SIGN FRACTURE CARE	\$2,000				5				5	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
INTERNATIONAL										
SILK ROAD MEDICAL, INC.		\$16,835				1			0	1
SKELETAL DYNAMICS LLC	\$19,449				82				60	0
SKELETAL KINETICS LLC	\$2,808				29				28	0
SKYLINE MEDICAL INC.	\$10,725				1				1	0
SMALL BONE INNOVATIONS INC.	\$254,462	\$56,268	\$5,589,073	\$2,134,969	269	14	28	28	205	4
SMARTHEALTH INC	\$8,150				170				57	0
SMITH & NEPHEW, INC.	\$12,271,492	\$122,902			18,795	18			7,628	30
SMITHS MEDICAL ASD, INC.	\$2,957				14				14	0
SOBI, INC	\$1,398				88				74	0
SOLANA SURGICAL, LLC	\$82,692				111				65	0
SOMERSAULT ORTHOPEDICS, INC	\$265		\$160,000	\$177,500	5		2	2	5	0
SONACARE MEDICAL, LLC	\$427,378		\$4,469,842	\$4,469,842	147		8	8	46	0
SONOCINE, INC.	\$210		\$1,382,782	\$1,382,782	2		17	17	19	0
SONOMA ORTHOPEDICS INC.	\$12,710				24				18	0
SORIN CRM USA, INC	\$91,770	\$17,798			432	11			194	8
SORIN GROUP USA, INC	\$133,058	\$65,549			886	19			318	22
SOUTHEAST CRYOTHERAPY LP	\$18,940		\$43,808	\$42,351	6		1	1	1	0
SOUTHERN SURGICAL SOLUTIONS, LLC	\$200,000		\$120,436	\$120,436	1		6	6	4	0
SOUTHTECH ORTHOPEDICS	\$4,289				15				13	0
SPECIALTY SPINE PRODUCTS, LLC			\$79,767	\$79,767			1	1	1	0
SPECIALTY SURGICAL INSTRUMENTATION	\$178,021				11				5	0
SPECTRUM PHARMACEUTICALS INC.	\$228,224	\$197,510			1,175	24			690	12
SPECTRUM SURGICAL	\$73,196				11				0	11

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
INSTRUMENTS CORP.										
SPINAL ELEMENTS, INC.	\$1,947				17				17	0
SPINAL MODULATION INC.	\$59,439		\$8,625	\$28,031	115		1	1	58	0
SPINE VIEW, INC.	\$9,737		\$185,823	\$208,570	21		6	6	24	0
SPINE WAVE, INC.	\$454,621		\$572,843	\$832,267	502		12	12	147	0
SPINEART USA INC	\$254,412				45				18	0
SPINEGUARD, INC.	\$48,751				52				27	0
SPINEOLOGY INC.	\$22,222	\$69,048	\$2,348,358	\$1,560,552	411	24	31	31	193	0
SPINESELECT, LLC	\$22,454		\$100,000	\$300,000	6		2	2	3	0
SPIRACUR INC.	\$18,700				131				104	0
SPIRATION, INC.	\$89,885	\$50,269			175	15			85	11
SPORTSTEK MEDICAL, INC	\$1,766				42				32	0
SPS MEDICAL SUPPLY CORP.	\$101				4				0	4
SRS MEDICAL SYSTEMS, INC.			\$3,920	\$3,920			2	2	2	0
SS WHITE BURS, INC.	\$30,701				66				46	0
ST. JUDE MEDICAL, INC.	\$3,085,706	\$400,163			14,658	116			2,701	86
STAAR SURGICAL COMPANY	\$17,166				51				39	0
STANDARD DIAGNOSTICS, INC.	\$2,370				1				1	0
STEREOTAXIS INC	\$40,111				66				54	0
STERILMED, INC.	\$3,254				11				3	0
STERIS CORPORATION	\$242,494				28				15	0
STRECK, INC.	\$13,932				11				1	10
STRYKER CORPORATION	\$8,399,816	\$381,787			15,187	56			4,980	113
SUCAMPO AG	\$3,782				2				1	0
SUCAMPO PHARMA AMERICAS, LLC	\$114,339	\$776			803	6			604	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
SUMMIT MEDICAL	\$13,493		\$282,078	\$282,078	6		3	3	8	0
SUMMIT PHARMACEUTICALS DBA ENEMEEZ, INC.	\$80				4				4	0
SUN PHARMACEUTICAL INDUSTRIES LIMITED		\$123,400				16			0	7
SUNOVION PHARMACEUTICALS INC.	\$6,165,837	\$65,506			53,081	13			14,245	4
SUNQUEST INFORMATION SYSTEMS, INC.	\$9,090				22				21	0
SUNSTAR AMERICAS, INC.	\$56,588				66				62	0
SUPERNUS PHARMACEUTICALS, INC.	\$561,912				4,484				1,930	0
SUPREME ORTHOPEDIC SYSTEMS, LLC	\$20,106				88				52	0
SUREFIRE MEDICAL, INC.	\$219,969				35				26	0
SURGI-CARE, INC.	\$5,574				9				7	2
SYNAPSE BIOMEDICAL INC	\$1,789				3				3	0
SYNCARDIA SYSTEMS, INC	\$119,776		\$8,290,921	\$8,290,921	201		26	26	64	3
SYNERGETICS USA, INC	\$209,795				106				73	0
SYNERGEYES, INC.	\$32,576				447				314	0
SYNTHES USA PRODUCTS LLC	\$13,268				367				141	0
SYSMEX AMERICA, INC.	\$34,974	\$25,000			30	3			17	8
SYSTAGENIX WOUND MANAGEMENT INC.	\$5,662				347				300	0
TACTILE SYSTEMS TECHNOLOGY INC	\$68,239		\$183,931	\$187,731	268		2	2	220	1
TAKEDA DEVELOPMENT CENTER AMERICAS, INC.	\$233,506	\$3,246,405			79	1,950			636	6
TAKEDA PHARMACEUTICAL COMPANY, LIMITED	\$54,458				30				7	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
TAKEDA PHARMACEUTICALS AMERICA, INC.	\$4,908,287				52,182				22,067	11
TAKEDA PHARMACEUTICALS INTERNATIONAL, INC.	\$408,159	\$2,644			330	9			81	0
TAKEDA PHARMACEUTICALS PUERTO RICO LLC	\$3,253				188				131	0
TAKEDA PHARMACEUTICALS U.S.A., INC.	\$4,396,004				9,504				4,434	0
TAKEDA VACCINES, INC.	\$17,456	\$570,710			7	6			3	2
TANDEM DIABETES CARE, INC.	\$255,007				1,298				776	20
TARO PHARMACEUTICALS USA, INC.	\$195,241	\$21,200			1,720	2			892	0
TEAM 1 ORTHOPAEDICS INC	\$6,561				35				30	0
TEAM_MAKENA_LLC	\$672				12				10	0
TEARLAB, CORP	\$62,946				304				285	0
TELEFLEX MEDICAL INCORPORATED	\$230,667				78				51	0
TENEX HEALTH INC.	\$49,953				250				164	0
TERATECH CORPORATION	\$1,823				8				8	0
TERUMO BCT, INC.	\$77,949				116				48	1
TERUMO CARDIOVASCULAR SYSTEMS CORPORATION	\$54,584	\$600			262	1			194	3
TERUMO MEDICAL CORPORATION	\$228,617	\$12,200			1,136	2			693	4
TEVA PHARMACEUTICALS USA, INC.	\$7,099,861	\$34,373			39,154	21			14,606	0
THE BINDING SITE INC.	\$467	\$665			32	1			32	1
THE CAMERON-EHLEN GROUP, INC.	\$43,195				110				86	0
THE MEDICINES COMPANY	\$757,307	\$4,000			2,693	1			1,603	27

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
THE NORTH CAROLINA MUTUAL WHOLESALE DRUG COMPANY INC			\$1,035,100	\$2,112,887			35	35	35	0
THE ORTHOPAEDIC IMPLANT COMPANY			\$710,000	\$1,420,000			20	20	20	0
THE SPECTRANETICS CORPORATION	\$821,029				2,177				883	2
THE WALMAN OPTICAL COMPANY	\$9,950				70				55	0
THEKEN SPINE, LLC	\$1,563				27				25	0
THERAGENICS CORPORATION	\$62,706				13				2	0
THERAKOS, INC.	\$59,145	\$62,688			52	1			43	1
THERAVANCE INC.	\$45,791				213				160	0
THERMO FISHER SCIENTIFIC ASHEVILLE LLC	\$7,388				7				0	6
THER-RX CORPORATION	\$9,969				720				646	0
THORATEC CORPORATION	\$1,035,344	\$135,260			4,902	43			2,278	47
THORATEC EUROPE LIMITED	\$38,083				8				5	0
THROMBOGENICS, INC.	\$333,619	\$14,977			1,448	2			690	0
TOLMAR, INC.	\$451	\$133,125			1	17			7	0
TOPCON CORPORATION	\$30,551				9				7	0
TOPCON MEDICAL SYSTEMS, INC.	\$29,634				47				41	0
TOPERA, INC.	\$190,521		\$2,148,043	\$682,116	34		8	8	25	3
TORAX MEDICAL, INC.	\$172,238	\$1,000			241	1			152	1
TORAY INTERNATIONAL AMERICA INC.	\$2,631				2				2	0
TOSHIBA AMERICA MEDICAL SYSTEMS, INC.	\$84,863	\$156,500			93	2			45	15
TOSHIBA MEDICAL RESEARCH		\$50,976				2			0	1

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
INSTITUTE USA INC.										
TOSHIBA MEDICAL SYSTEMS CORPORATION	\$332	\$6,132			2	1			1	1
TOSOH BIOSCIENCE, INC.	\$80,345				209				176	0
TRANSENERIX, INC.	\$158,931		\$28,409	\$782,875	119		3	3	21	0
TRANSONIC SYSTEMS INC.	\$21,776				5				5	0
TRASLATIONAL CANCER DRUGS PHARMA S.L.		\$10,468				1			0	1
TRILLIANT SURGICAL LTD.	\$7,851		\$125,000	\$220,000	52		4	4	42	0
TRIEME MEDICAL LLC	\$37,902		\$256,545	\$756,733	181		3	3	99	1
TRI-STATE CRYOSURGICAL PARTNERSHIPS LP	\$88,310		\$239,220	\$322,792	98		30	30	32	0
TRIVASCULAR, INC.	\$202,185				1,672				773	1
TULSA DENTAL PRODUCTS LLC	\$826,818				2,328				1,505	1
TURN-KEY MEDICAL, INC.	\$499				6				6	0
TYRX, INC.	\$102,297	\$500			207	2			181	1
U.S.S.C. PUERTO RICO, INC.	\$53,559				106				83	1
UCB BIOSCIENCES INC.	\$10,669	\$478,432			27	97			59	8
UCB GMBH	\$12,266				7				2	0
UCB SA	\$74,990				115				16	0
UCB, INC.	\$727,029	\$20,260			18,250	45			7,760	0
UHS SURGICAL SERVICES, INC.	\$2,520				58				54	0
ULTRADENT PRODUCTS INC	\$21,150				65				65	0
UNITED THERAPEUTICS CORPORATION	\$1,683,553	\$1,481,497			1,675	207			989	12
UNIVERSAL HOSPITAL SERVICES, INC.	\$262				12				12	0
UNIVERSAL MEDICAL, INC.	\$62,047		\$729,218	\$729,218	5		1	1	3	0

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
UPSHER-SMITH LABORATORIES INC.	\$469,106	\$70,812			745	4			483	2
UROLOGIX, INC.	\$22,388				403				403	0
UROPLASTY, INC.	\$178,315				58				16	0
US ENDOSCOPY	\$320,887				231				181	3
US WORLDMEDS, LLC	\$657,493	\$35,888			3,087	10			937	0
VALEANT PHARMACEUTICALS NORTH AMERICA LLC	\$835,959	\$468,455			8,461	29			4,257	1
VALERITAS, INC.	\$278,999	\$38,100			3,934	5			2,163	0
VALIDUS PHARMACEUTICALS LLC	\$46,142				261				39	0
VANSEN PHARMA INC.	\$7,866				400				314	0
VARIAN MEDICAL SYSTEMS, INC.	\$410,075	\$127,490			542	4			290	7
VASCULAR DYNAMICS, INC.	\$5,985				10				4	0
VASCULAR SOLUTIONS, INC.	\$71,103				702				554	11
VASONOVA INC.	\$1,531				3				2	0
VECTOR SURGICAL, LLC		\$7,550	\$1	\$1,500,000		1	1	1	2	0
VENTANA MEDICAL SYSTEMS, INC.	\$258,543	\$360,443			156	48			56	16
VERAN MEDICAL TECHNOLOGIES, INC.	\$38,632				94				65	0
VERATHON INC.	\$30				1				1	0
VERMILLION, INC.	\$40,418				168				160	0
VERTEBRAL TECHNOLOGIES, INC.	\$54,775		\$3,471,317	\$4,582,830	48		49	49	57	0
VERTEX PHARMACEUTICALS INCORPORATED	\$1,516,315	\$487,676			4,143	29			2,409	22
VERTIFLEX, INC.	\$26,069		\$10,363	\$8,870	59		2	2	17	0
VG INNOVATIONS, LLC	\$683				7				5	0
VIDACARE CORPORATION	\$2,203	\$12,861			17	1			16	1

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
VIDARA THERAPEUTICS INC.	\$3,218				66				58	3
VIEWRAY INC	\$115,712		\$1,374,223	\$2,116,700	33		11	11	37	0
VIIV HEALTHCARE COMPANY	\$875,518	\$818,205			1,871	265			330	5
VIOPTIX INC	\$2,606				12				11	0
VIRACOR-IBT LABORATORIES, INC.	\$165				3				3	0
VIROPHARMA INCORPORATED	\$311,384	\$9,271			1,157	3			737	3
VISAGE IMAGING, INC	\$6,000				3				2	1
VISION QUEST INDUSTRIES INC.	\$105,527	\$2,300			107	1			108	0
VISIONARY OPTICS LLC	\$177,992		\$1,000	\$156,649	9		2	2	9	0
VISIONCARE OPHTHALMIC TECHNOLOGIES, INC.	\$147,311	\$4,509			272	1			177	1
VISTA ORTHOPEDICS, LLC			\$3,406	\$3,406			4	4	3	0
VISUALASE, INC.	\$243,488		\$13,663	\$13,663	224		1	1	121	8
VITAL ART AND SCIENCE LLC	\$2,100		\$10,000	\$330,941	1		1	1	1	0
VITAL IMAGES, INC.	\$50,322	\$47,300			77	2			35	4
VITAPHONE_USA_CORPORATION	\$1,350				68				67	0
VIVEX BIOMEDICAL, INC.	\$106,727		\$2,361,400	\$3,785,118	10		22	22	17	0
VIVUS INC	\$260,346	\$35,489			3,378	9			1,766	3
VOLCANO CORPORATION	\$446,294				1,050				527	13
VOLPARA SOLUTIONS LTD	\$5,000				1				1	0
VUCOMP, INC.	\$24,722		\$638,908	\$441,734	30		4	4	25	3
W. L. GORE & ASSOCIATES, INC.	\$1,525,449	\$8,447			6,878	3			2,160	9
WAKO LIFE SCIENCES, INC.	\$8,671				20				16	0
WARDLOW ENTERPRISES	\$5,865				18				13	0
WARNER CHILCOTT LLC	\$1,946,574	\$13,571			30,115	4			16,112	7

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
WAVETEC VISION SYSTEMS, INC.	\$79,748	\$9,250	\$0	\$3,500	27	1	2	2	20	0
WELCH ALLYN	\$36,055				8				5	0
WENZEL SPINE, INC.	\$68	\$100	\$901,275	\$2,805,606	2	1	6	6	8	1
WERFEN USA LLC	\$1,012				2				2	0
WEST COAST CRYOTHERAPY LP	\$46,984		\$378,401	\$252,706	90		19	19	19	0
WESTPAC PARTNERS, LP			\$335,000	\$513,622			6	6	6	0
WHIP MIX CORPORATION			\$2	\$683,293			2	2	2	0
WHITE BOX ORTHOPEDICS, LLC	\$636				4				2	0
WILSON COOK MEDICAL INCORPORATED	\$753,881				502				319	3
WOCKHARDT USA LLC	\$14,611				968				743	0
WOUND CARE TECHNOLOGIES, INC.	\$1,724		\$220,000	\$286,000	18		5	5	19	0
WRIGHT MEDICAL TECHNOLOGY, INC.	\$3,842,905	\$44,058			3,847	3			1,013	3
WYETH LLC		\$37,978				2			0	1
WYETH PHARMACEUTICALS INC	\$8,513				10				8	1
XENOPORT INC.	\$342,496				2,318				1,188	0
XHALE, INC.	\$2,627		\$2,501,850	\$4,712,629	2		14	14	14	0
X-SPINE SYSTEMS, INC.	\$67,097				70				39	0
YOUNG DENTAL MANUFACTURING I, LLC	\$14,213				237				212	1
YOUNG OS LLC	\$28,545				25				24	1
YOUNG PS ACQUISITIONS, LLC	\$4,720				242				229	0
ZIEMER USA	\$48				1				1	0
ZILA, INC.	\$144,977				76				14	0
ZIMMER HOLDING INC	\$17,285,711	\$146,615			9,983	8			4,686	17

Open Payments Program Report to Congress

Name of Applicable Manufacturer & Applicable Group Purchasing Organization Making Payment	Dollar Amounts				Number of Transactions				Number of Physicians	Number of Teaching Hospitals
	General Identified	Research Identified	Investment Identified	Interest Identified	General Identified	Research Identified	Investment Identified	Interest Identified		
ZOGENIX INC.	\$69,195				1,541				548	0
ZOLL CIRCULATION INC	\$184,984	\$48,714			39	25			7	31
ZOLL LIFECOR CORPORATION	\$388,078	\$7,238			10,547	1			5,694	25
ZOLL MEDICAL CORPORATION	\$73,115				48				34	4
ZONARE MEDICAL SYSTEMS, INC.	\$33,942				2				1	1
ZYGA TECHNOLOGY INC	\$68,078				71				59	0